

CURRICULUM VITAE

Professor Eva Segelov

Home address: Junkerngasse 5, 3011 Bern, Switzerland
Nationality: Australian
Mobile: +41798040089
Work address: Department of Clinical Research, Faculty of Medicine, University of Bern
Email: eva.segelov@unibe.ch

ACADEMIC AND PROFESSIONAL QUALIFICATIONS

M.B., B.S. (Hons 1) University of Sydney 1988

Fellow of the Royal Australasian College of Physicians 1994-2024
(Specialist in Medical Oncology)

PhD, University of Sydney 1998

CURRENT APPOINTMENT

Dec 2022-

Full Professor (Ordinarius) and Director of the Department of Clinical Research, Faculty of Medicine, University of Bern, Switzerland and University Cancer Centre, Inselspital, Bern.

PREVIOUS APPOINTMENTS

Feb 2017 – Aug 2022: Professor/ Director of Oncology, Monash University and Monash Health, Melbourne. Chair, Cancer and Blood Theme, Monash Partners Comprehensive Cancer Consortium. Acting Director of Southern Melbourne Integrated Cancer Services (SMICS) 2017-8.
Head, Oncology Translational Laboratory, School of Clinical Sciences, Monash University
Honorary Associate, NHMRC Clinical Trials Centre, University of Sydney, Australia.
Guest Professor, Shanghai Jiatong University, China, 2017
Visiting Professor, Department Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO). Faculty of Medicine and Health Sciences, University of Antwerp 2020-

PREVIOUS APPOINTMENTS

2004 –2016: Associate Professor of Medicine, St Vincent's Clinical School, University of New South Wales (UNSW) (2007), previously Senior Lecturer in Medicine
Director of Conjoint Liaison, Faculty of Medicine, UNSW (2007-13)
Director of Medical Student Education, St Vincent's Clinical School (2007-13)
Senior Specialist in Medical Oncology, St Vincent's Hospital, St Vincent's Private Hospital, Sydney
Honorary Associate, NHMRC Trials Centre, University of Sydney

1998-2004: Senior Lecturer in Medicine, South Western Sydney Clinical School, UNSW
Director of Medical Student Education, South Western Sydney Clinical School, UNSW
Consultant Medical Oncologist, Liverpool Hospital
Head, Cancer Research Laboratories, South Western Sydney Clinical School, UNSW

1994-1993: NH&MRC Research Fellow, Department of Medical Oncology, Westmead Hospital, Sydney
 Locum Staff Specialist in Medical Oncology, Liverpool Hospital
 Tutor, Graduate Medical Programme, University of Sydney
 Lecturer, Overseas Doctors Training Programme, NSW Health
 Intern, RMO, Registrar, Advanced Trainee in Medical Oncology: Royal Prince Alfred Hospital, Westmead Hospital, and Prince of Wales Hospitals, Sydney.

INTERNATIONAL ROLES: Leadership, conference convenor and committees

- Board Member, Australia Swiss Academic Innovation Network- ASAIN
- Co-Founder, Commonwealth Neuroendocrine Tumour Society (CommNETs): an international research collaboration which I established in 2015 between Australia, Canada and New Zealand
- Founding committee member, International Multidisciplinary Anal Cancer Consortium (IMACC)
- Member, International Adjuvant Aspirin Trialist Consortium
- American Society of Clinical Oncology (ASCO)
 - Program Committee member, inaugural “Breakthrough: A Global Summit for Oncology Innovators meeting, Oct 2019, Bangkok” (only Australian invited)
 - Selector of Internship awardees, ASCO 2018-
 - Journal of Clinical Oncology- Global Oncology (JCO-Global Oncology; an ASCO journal)
 - Associate Editor 2018- ; previous Editorial Board Member 2015-2017
 - Guest Editor, Inaugural Special Edition of Journal of Global Oncology “Cancer in Indigenous Communities”- in preparation; for publication Mar 2019”, Special edition on Cancer in the Asia-Pacific Region.
- European Society of Medical Oncology (ESMO) Faculty Group member
 - CUP, Endocrine Tumours and Others 2017-2020
 - Gastrointestinal Faculty Group 2018-2021
 - ESMO faculty member for the NETs and Endocrine Tumours faculty group 2021-2025
 - Member, Magnitude of Clinical Benefit Scale Committee, 2023-
- ESMO/European Association for Cancer Research (EACR) Annual Scientific Congress
 - Scientific Sub-Committee member 2018-2020
- The First International Multidisciplinary Anal Cancer Conference 2021, Organising committee member, November, virtual meeting (Denmark)
- ESMO Asia Annual Scientific Meeting: Track co-Chair, Gastrointestinal Cancer, 2017
- Australasian Gastro-Intestinal Trials Group (AGITG):
 - Board Member, 2014-2020
 - Scientific Advisory Committee member, 2004-2018
 - Lower Gastrointestinal Cancer Working Group 2013-18
 - International Development Committee, AGITG 2018-
- Member, Data Safety Monitoring Committee, TransTasman Radiation Oncology group 2015-2021
- Associate Editor, JCO GO; Editorial Board: BMC Cancer 2020-,
- Conference Convenor of:
 - Australasian GastroIntestinal Trials Group Annual Scientific Meeting 2015-2019
 - Commonwealth Neuroendocrine Tumour Society (CommNETS) Annual Scientific Meeting 2015-
 - Clinical Oncology Society of Australia Annual Scientific Meeting 2008-2011
 - Tailored Therapies in Colorectal Cancer National meeting, 2012
- Conference Convening committee:
 - IMACC (International Multidisciplinary Anal Cancer Consortium) Annual Scientific Meetings 2021, 2023.
 - AGITG Annual Scientific Meetings 2011-2014
 - Controversies in Breast Cancer International Meeting (COBRA): 2015

- L’Oreal-UNESCO For Women in Science International Fellowships, Jury member Australia and New Zealand 2018-2022.
- Binational Colorectal Cancer Audit Operational Committee, 2021-2022.
- International grant reviewer: Cancer Research UK, European Organization for Treatment of Cancer (EORTC), Swiss Cancer Research, McGill University DNA to RNA (D2R) Foundational Projects Program, National Medical Research Singapore, Health Research Council New Zealand

International clinical trial roles

- Clinical Lead (one of 4 International Principal Investigators) ASCOLT trial and International Head of Translational Research for the ASCOLT study.
- Chair, Short Course Oncology Treatment Scientific Access Committee – oversight of use of tissue and blood samples (>5000) collected on the international SCOT trial
- Founding member, International Adjuvant Aspirin Trialists Group
- Chair, Clinical Trials Working Group, Commonwealth Neuroendocrine Tumour Collaboration
- Principal international investigator, ICECREAM clinical trial
- Principal Australian investigator, multiple clinical trials (SCOT, InterAACT, QUASAR2)
- Member, OzSAGE, leading advice on COVID-19 and immunosuppressed people

University of Bern roles

- 2024- Faculty of Medicine representative, Research Commission of the University of Bern
- 2024- Scientific Committee for the Swiss Gender Medicine Symposium
- 2024- Board Member, Female Empowerment in Life Sciences Board (FELS)
- 2023- Steering Committee of CAIM (Centre for AI in Medicine)
- 2023- Faculty of Medicine Commission for national and international relations.
- 2023- Graduate School for Health Sciences Expert Committee
- 2023- Committee member, Nachwuchsförderungs-Grants für patientenorientierte Forschung
- 2023- Umhabilitation, Habil committee Faculty of Medicine - Chair for multiple applications
- 2023- Faculty of Medicine Commission for national and international relations- grant allocation
- 2023- FELS network (Female Empowerment in Life Science)

NATIONAL ROLES AND COMMITTEES

Switzerland

- Member, organizing committee, Swiss Gender Medicine Symposium, Bern Oct 2025.
- Board of Clinical Directors, Swiss Clinical Trials Organisation

Australia

- Chair, Gastrointestinal Group & Council Member, Clinical Oncological Society of Australia 2010-19
- *Multiple activities including advocacy, advice regarding policy and submissions to government*
- Chair, Cancer and Blood Theme, Monash Partners Comprehensive Cancer Consortium (MPCCC); division of the Monash Partners Academic Health Science Alliance 2017-
- *Regular liaison with DHHS Victoria regarding service and funding for cancer*
- Chair, Australia Council on Healthcare Standards Oncology Clinical Indicator Development Core Group 2018-

- Chair, Clinical Trials Expert Group of the Victorian Cancer COVID-19 Network 2021-
- Member, Cancer Council Victoria Clinical Trials Advisory Committee (CTAC) 2020-
- Cancer Australia:
 - COVID-19 Vaccine and Cancer Virtual Round table Feb 2021
 - COVID-19 Recovery Round table July 2020
- Co-Chair, ReViTALISE Project Advisory Committee of the Regional Trials Network 2021-
Governance group advising spending of approx. \$20M MRFF and state funding
- Colorectal Surgical Society of Australia and New Zealand Binational Colorectal Cancer Audit (BCCA) – member of Operational Committee 2021-
- Member, Cancer, COVID-19 and You advisory committee of Cancer Council Victoria 2022
- Member, NHMRC Assigners Academy 2017-2020; NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme reviewer 2014-; NHRMC Fellowship reviewer, 2012
- Member, Working Group, 2021-2024 VCCC Strategic Planning Group Program 8: Build on initiatives to meet the needs of vulnerable groups
- Health Purchasing Victoria: Product Reference Group 2018-9MPCCC/VCCC action committee, 2017- Cancer Council Victoria, Medical and Scientific Committee 2017-
- Victorian Medical Research Future Fund (MRFF) Cancer Grand Challenge Working Party 2018- Cancer Council Australia, Clinical Guidelines Network, Subcommittee member, 2016
- NSW Cancer Institute Standard Treatment Protocols (eviQ) committee 2004- NSW Cancer Survivors Centre, Board Member, 2010-15
- Member and Acting Chair, Human Research Ethics Committee University of NSW 2004-7 Faculty of Medicine representative, Gender Equity Advisory Committee UNSW 2008-9 Pfizer Australia Young Investigator Cancer Research Grant 2011
- Pfizer Australia Cancer Grant reviewer 2009
- 2004 NSW Cancer Council project grants reviewer; Carrick expert assessor, Institute Fellowship Scheme; 2007 St Vincent's Clinic Foundation grant reviewer 2005-7 South Western Sydney Health Research Foundation 2001-2
- Conference Convenor/ course developer for multiple national Seminal Advances in Oncology courses: AGITG Preceptorship in Colorectal Cancer, 2013- 2018; ANZUP Preceptorship in Genitourinary Cancer, 2015-2018; ALTG Preceptorship in Lung Cancer, 2015.
- Inaugural Co-Convenor, Advanced Trainee Education weekends prior to Annual Scientific Meeting of COSA, 2010-.
- Australasian Maternity Outcomes Surveillance System Advisory Board member, gestational breast cancer project
- Australasian Tele-Trial Model: Access to clinical trials closer to home using telehealth. Policy document, Clinical Oncology Society of Australia (Concept development and implementation co-author, member, steering committee)

Oncology service invited external reviews

2018 Auckland Hospital Oncology Clinical Trials Unit- commissioned external review; Team Leader
2017 Austin Hospital Medical Oncology Department- commissioned external review; Team Leader

INVITED SPEAKER: International meetings

September 2025. International Multidisciplinary Anal Cancer Consortium 3rd Annual Scientific Meeting, Manchester, Conference committee member and speaker: The role of Patient and Public Engagement in Anal Cancer Research: a practical guide to implementation

March 2025. 1st International ctDNA-RECIST Symposium, Aarhus, Denmark- invited speaker.

Nov 2023. International Multidisciplinary Anal Cancer Consortium 2nd Annual Scientific Meeting, Rome, Conference committee member and speaker.

Aug 2022. Invited panel Member: “Real world challenges for women in oncology and proposed solutions”. Virtual platform.

May 2022. American Society of Clinical Oncology Annual Scientific Meeting. Invited panel member, Women in Oncology Working Group, Chicago.

Nov 2021. “First International Multidisciplinary anal cancer conference, Aarhus, The Netherlands. Convening committee and invited speaker “Systemic therapies for local and locally advanced cancers”

Oct 2021: European Society of Medical Oncology (ESMO). Invited speaker: Oral presentation- unable to attend in person so allocated to select prizes for NET poster session.

Oct 2021: AGITG Annual Scientific Meeting (virtual). Opening Plenary + special session panel member

Aug 2021: Faculty Grupo Brasileiro de Tumores Gastrointestinais, Brazil: virtual conference.

May 2021. International Multidisciplinary Anal Cancer Conference, webinar. Convenor and speaker

Nov 2020. First International Multidisciplinary anal cancer conference, Aarhus, The Netherlands- virtual webinar

Oct 2020: European Society of Medical Oncology . Invited speaker: Oral presentations, NET session

Oct 2019: American Society of Medical Oncology Breakthrough Inaugural Meeting: Bangkok, session chair (multiple)

Sept 2019: European Society of Medical Oncology Annual Meeting: Lung Neuroendocrine educational session, Barcelona, invited speaker

May 2019: International Gastric Cancer Conference, Prague, Session Chair

April 2018: 12th Congress of the World Federation of Nuclear Medicine and Biology, Melbourne, invited speaker

Nov 2017: European Society of Medical Oncology (ESMO) Asia ASM. Invited speaker: Integrative molecular analysis of oesophagogastric cancer: lessons from colorectal cancer. Singapore.

Nov 2017: Springer Healthcare Independent Medical Education, ESMO Asia ASM, Singapore: Advances in gastric cancer care symposium.

Oct 2017: International Guest speaker, North American Neuroendocrine Society Annual Scientific Meeting, Philadelphia. Multiple presentations

Sept 2017: Guest speaker, symposium "110 years of discovery of NET", European Society of Medical Oncology Annual Scientific Meeting, Madrid

Mar 2017: Guest Professor, Shanghai Jiao Tong University, Shanghai China, School of Medicine lecture series "Cancer Epidemiology and Prevention"

Mar 2017: Invited panel member, INCA summit meeting, 14th Annual Conference of the European Society of Neuroendocrine Tumours, Barcelona

Jan 2017: Guest Professorial Lecturer, Dept of Oncology, Auckland University

Jan 2017: Guest Professorial Lecturer, Dept of Oncology, University of Otago, New Zealand

Dec 2016-: AGITG Expert Opinion on management of Pancreatic Cancer, satellite meeting at ESMO Asia Annual Scientific Meeting, Singapore- Convenor and speaker

Aug 2016: North American Neuroendocrine Tumour Society Expert consensus meeting for guideline development for management of small bowel Neuroendocrine tumours- invited international participant

Nov 2015: Invited international guest, Canadian Consensus guidelines for the care of NETs patients, Honolulu

Nov 2015: Convenor and Chair CommNETS Inaugural meeting and Principal Investigator for Modified Delphi Consensus Project “Gaps in Global neuroendocrine research” project

Oct 2015: CoBRA World Congress on Controversies in Breast Cancer, Melbourne. Speaker (multiple presentations) and session convenor

Aug 2013: New Zealand: Invited international expert: National Rectal Cancer Summit

Nov 2012: Jinan, China: Keynote lecture, 9th Chinese National Academic Congress of Colorectal Cancer:

Nov 2012: Shanghai, China, International speaker: Seminar for Individualized Treatment of Cancer

Oct 2012: Sydney International Breast Cancer Conference: Breakfast Symposium

Aug 2012: Auckland. Australian and New Zealand Neuroendocrine Tumour Meeting: Invited speaker

May 2012: Royal Australasian College of Surgeons Annual Scientific Meeting, Kuala Lumpur, Invited guest of Surgical Oncology Group. Multiple presentations:

Sept 2010: Oxford University: Oxford Clinical Trials Meeting: Invited speaker (opening presentation)

Aug 2008 MOGA/FRO/NZSO/NZACS Joint Scientific Meeting Christchurch, Invited speaker

Sept 2007 Third International Clinical Trials Symposium, Sydney: Speaker, Plenary Debate

National meetings (Australia)

Nov 2021: Medical Oncology Group of Australia 2021 Immuno-Oncology Symposium -

Nov 2021: COSA ASM – invited Plenary speaker plus multiple oral and poster abstracts (>10)

Sept 2021: ESMO ASM- due to inability to attend in person, invited speaker reallocated to be “Best of Poster” judge.

Multiple 2020-2021: VCCC Monday Lunch time seminars- speaker and panelist; Monday Lunch Livestream: Understanding the safety and efficacy of the COVID-19 vaccines in people with cancer - The SerOzNET study Aug 2021; COVID-19 and Cancer in Victoria: impacts and opportunities for the clinical trial sector; Jun 2020 COVID-19 and Cancer in Victoria: a Coordinated Clinical Response 23 Mar 2020

Multiple national education meetings (Chair and speaker), for Limbic Pty Ltd; average > 400 listeners; includes: ESMO 2021: GI cancer highlights through an Australian lens Webinar Oct 2021; ESMO 2021: Gamechangers Webinar: 30.9. 2021; ASCO 2021: GI cancer highlights through an Australian lens 15.7.2021; ASCO Game-changers 2021 23.7.21; Highlights from ESMO 2020 29.9.20

Sept 2021: NET update and future directions; invited speaker; Flinders Foundation and the Medical Oncology Training of South Australia Committee

Aug 2021: Medical Oncology Group of Australia Annual Scientific Meeting: invited speaker for the Young Oncologists Program

Private Cancer Physicians of Australia: meeting July 2021

Nov 2020: 47th Annual Scientific Meeting of the Clinical Oncological Society of Australia (COSA ASM)

Virtual meeting: invited speaker: “Practical considerations for treating patients with cancer in the COVID-19 pandemic”; oral presentation: Best of the Best Orals - Quality & Safety “Developing clinical indicators for Oncology: the inaugural *indicator* set for The Australian Council on Healthcare Standards (ACHS); invited discussant: Best of the Best orals: Basic and Translational Research- 2 sessions.; Multiple other presentations – see abstracts

Sep 2020: Invited speaker: 14th Colorectal Cancer Conference, Victorian Comprehensive Cancer Centre, Melbourne (deferred to 2021)

Sept 2019: Victorian Comprehensive Cancer Centre Research Conference: Invited Speaker, debate.

Nov 2018: COSA ASM and Annual Trainees Weekend, Perth, invited speaker and Session Chair Nov 2018: Sydney Colorectal Conference, Sydney, invited speaker

Aug 2018: Immuno-Oncology Forum, Medical Oncology Group Australia, Adelaide, invited speaker

May 2018: Sydney Vital and STEaM Neuroendocrine Tumor Preceptorship, invited speaker

Nov 2017: Invited discussant Best of the Best Posters, COSA ASM, Sydney

Sep 2017: Invited speaker: 11th Colorectal Cancer Conference, Victorian Comprehensive Cancer Centre, Melbourne.

Aug 2017 Chair, “Difficult cases in Pancreatic Cancer” symposium at Medical Oncology Group of Australia Annual Meeting, Melbourne,

Aug 2017 Speaker: Trials endpoints debate, breakfast session at Medical Oncology Group of Australia Annual Meeting, Melbourne,

May 2017 Private Cancer Physicians of Australia National Trainee Program, Invited Speaker Sept 2016 AGITG ASM Sydney, Presenter and Session Chair, multiple sessions.

Dec 2015: Convenor and Preceptor, 3rd AGITG National Preceptorship in colorectal cancer, Melbourne.

Nov 2015: Convenor &Preceptor, Inaugural ANZUP National Preceptorship in prostate cancer, 2015, Melbourne.

Sept 2015: AGITG ASM Sydney, Presenter and Session Chair, multiple sessions.
 Mar 2015: Convenor and Preceptor, Inaugural ALTG National Preceptorship in Lung cancer, Sydney.
 July 2015: AMGEN symposium on colorectal cancer, Sydney
 Sept 2014: Convenor and Preceptor, 2nd AGITG National Preceptorship in colorectal cancer, Sydney.
 2014: Invited speaker, Tailored Therapies Meeting, Sydney.
 Aug 2014: Invited speaker: AGITG ASM Brisbane, Presenter and Session Chair, multiple sessions.
 Oct 2013: Invited speaker: AGITG ASM Melbourne, Presenter and Session Chair, multiple sessions.
 Oct 2013: Invited speaker: Australian Gastroenterology Week Melbourne
 Aug 2013: Convenor and Preceptor, AGITG Preceptorship in colorectal cancer, Melbourne.
 Feb 2013: Tailored Therapies - A Focus on Colorectal Cancer. Invited speaker, Canberra 2013:
 11th Annual HOTT Symposium. Invited debater (x2 talks), Sydney March
 2012: Sydney International Breast Cancer Conference. Practical perspectives on managing challenging scenarios and case studies, Oct 2012, Sydney.
 2012: PCPA Annual Scientific Meeting Scientific Session – “Challenging the Dogma - Three Vital Questions Answered”. Session Chair and facilitator. Oct 2012
 2012: Facilitator, panel discussion at consumer forum, Australian New Zealand Urological Prostate Trials Group, July 2012
 May 2012 Meeting convenor and speaker, Tailored Therapies in colorectal cancer,
 Apr 2011 Tailored Therapies Meeting, Focus on colorectal cancer, February 2011: multiple sessions
 2003-2022 Australian Gastrointestinal Trials Group Annual Scientific Meeting 2003-2022, Presenter and Session Chair, multiple sessions.
 2003-2022 Medical Oncology Group of Australia Annual Scientific Meeting - multiple sessions

State meetings

Nov 2021: Cancer Institute NSW webinar: how the cancer system has responded to the COVID19 pandemic.
 June 2020: 17th Annual Victorian Post ASCO Meeting: Update in GI cancer
 June 2019: 16th Annual Victorian Post ASCO Meeting: Update in GI cancer
 March 2018: 16th Interdisciplinary Peer Meeting Albury Wodonga Health (AWH), Guest Speaker
 July 2017: Invited interstate guest of Western Australia Cancer Council, presenting to public forum, Western Australian Clinical Oncology Group and Fiona Stanley Hospital Grand Rounds
 June 2017: 15th Annual Victorian Post ASCO Meeting: Update in GI cancer
 July 2017: Monash University Translational Research Symposium, Alfred Hospital, Victoria
 Sept 2016: Chair, What’s new in neuroendocrine tumours? Sydney Vital seminar Dec 2015: Invited speaker: debate: Sydney Catalyst
 June 2014: Guest speaker, Adelaide Tumour Group post-ASCO meeting: Update on CRC from ASCO
 Oct 2012: NETwork: NSW Neuroendocrine Masterclass- Faculty member 2008-
 2014 Basic Sciences of Oncology (NSW Cancer Institute) Guest lecturer 2012-6:
 NSW Cancer Institute eviQ Pharmacy group- Guest speaker
 July 2012 Update on NET for pathologists, Sydney, Speaker,
 Feb 2012 Update from the eNETs conference, Sydney, Chair and speaker
 Sept 2011-12 Neuroendocrine masterclass, Chair and speaker
 June 2010-12 NSW Scientific Review Update Meeting of ASCO Proceedings, Sydney, Chair and speaker,
 2009, 2010 Introduction to Clinical Trials Course, University of Sydney- guest speaker (received best feedback of course): *Informed Consent*
 Aug 2010 Best of ASCO meeting, Sydney: Chair and speaker
 May 2010 ACTNOW meeting (run by COSA) - Convenor and speaker, multiple presentations
 2010 Garvan Institute Public Seminar
 2008 NSW Update on San Antonio Breast Conference
 2007 Introduction to Cancer Nursing St Vincent’s Hospital
 2007 Eastern Suburbs GP Association Monthly Lectures

2006-8- Presenter, ACTNOW meeting, (Roche Pharmaceuticals)
2005 Seminar Series- Department of Genetics, Royal Prince Alfred Hospital
2002 Seminar Series- South Western Sydney Clinical School, 2002-3
Community Talks- multiple, including 2011, 2013 NSW Cancer Council Soiree series “Understanding the differences in breast cancer”.

AWARDS/PRIZES

- 2022 John Zalcberg Award for Excellence in AGITG Research
- 2020 Most Outstanding Site award- Monash Health Oncology Clinical Trials, awarded at Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting, Melbourne, Australia
- 2016 Best New Concept award- Eva Segelov, awarded at Australian Gastrointestinal Trials Group Annual Scientific Meeting 2016 Brisbane
- Certificate of Outstanding Service, Clinical Oncological Society of Australia, 2010
- Vice Chancellors Award for Teaching Excellence, University of NSW, 2006
- Merck, Sharp and Dohme (Aust) Research Student Poster Award. UNSW April, 2003
- NSW Cancer Council Travel Award for study in an overseas laboratory, 1996.
- AMRAD Young Investigator Award 1995. 33rd Annual Scientific Meeting of the Australian Society for Medical Research, Melbourne 1995.
- MOG-Neupogen Travel Award 1994; for presentation at Keystone Conference on DNA repair, New Mexico, USA, March 1995.
- Burroughs Wellcome Prize for Pharmacology, Year III Medicine, University of Sydney, 1985.

RESEARCH STUDENT SUPERVISION

PhD, Monash University

Main supervisor

Dr D Day 2018- 2025 (part time)
Dr A Body 2021- 2024 (part time)
Dr C McLaren 2022-2022 (part time)
Dr A McCartney 2022-2022 (part time)

Co-supervisor

Dr S Tan 2022- 2025 (part time)
Ms N McPhee 2019- (part time)
Dr E Kwan 2017-2020

Honours, BMed Sci

-Dr T. Chen (primary supervisor) BMedSci (Hons), completed 2019
-C. Naidu (primary supervisor) BMedSci (Hons), completed 2018
-C Lawley (UNSW Med) 2016, N da Silva 2015 (cosupervisor)

2009-14 Independent Learning Projects, UNSW T Scheinberg, J Meagher, T Lee, A Ballin, A Malik

Thesis reviews

PhD University of Queensland – candidate 40348052, 2017
Hons candidate, Uni Sydney, 2012
PhD candidate, University of Sydney 2005

BSc Hons candidate, UNSW, 2005
BSc Hons candidate, UNSW, 2006 (Supervisor: Dr Megan Hitchens)
Independent Learning Project assessor (multiple) 2008-

COMMUNITY ENGAGEMENT

Interview for Beobachter magazine - [Immuntherapie: «Die Krebsmedizin hat sich massiv verändert» | Patreon](#), Nov 2025

Cancer conversations Nov 2021, NSW Cancer Institute
COVID-19 resources for patients: ABC Drive radio interview 2020; SBS radio – COVID-19 resources for CALD communities 2020; Simplify Cancer Podcast (Cancer & COVID-19 Pandemic) 2020
Podcast: Guest interviewee, WSOU: Leadership with Darrell W. Gunter
Guest expert, “Alternative Truth”, Dec 2018, producer: Podcast one for Triple M media
Chief of diagnosis and oncology care, Compassionate Medical Program to Solomon Islands, St Vincent’s Hospital 2007-2016
Invited interstate guest of Western Australia Cancer Council, presenting to WA Cancer Council public forum, State Library, July 2017
2011, 2013 NSW Cancer Council Soiree series
Dr Hope Afternoon Tea (supporting Monash Oncology Clinical Trials), Keynote Speaker, Nov 2018
Dr Hope Fundraising Gala Ball (supporting Oncology Clinical Trials), Keynote Speaker, April 2018
Santa Sabina College “Maintaining Hope” guest speaker, Oct 2014
Keynote speaker, Business Insights Forum, Commonwealth Bank of Australia Institutional & Business Banking Risk Management Nov 2012
Keynote address, Field of Women, St Vincent’s Hospital October 2012
Facilitator, consumer forum, Australian New Zealand Urological Prostate Trials Group, July 2012
Invited speaker, Garvan Institute Open Day, Sydney 2011

PROFESSIONAL SOCIETY MEMBERSHIPS

Member, American Society of Clinical Oncology (ASCO)
Member, European Society of Medical Oncology (ESMO)
Council Member and Chair of Gastrointestinal Cancer Group, Clinical Oncological Society of Australia (COSA)
Member, Medical Oncology Group of Australia (MOGA)
Board and Committee Member, Australian Gastrointestinal Trials Group (AGITG)
Co-founder, Commonwealth Neuroendocrine Tumour Society (CommNETS)
Member, Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
APHRA member MED0001142136

PUBLICATIONS (ORCID 0000-0002-4410-6144; SCOPUS 6603229161)

2026

Submitted:

SEGELOV E*, Li S, Li I, Mouradov D, Yip S, Day D, Jeffrey G, Zielinski R, Nott L, Sunx Y, Ho G, Chao T, Rahman N, Foo E, Chia J, gebiski V, Toh H, Sieber O, Simes J. Adjuvant aspirin for colorectal cancer with *PIK3CA*-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. submitted Jan 2026 to *The Lancet Gastroenterology & Hepatology*

Riggi E, **SEGELOV E**, di Tanna G. Target Trial Emulation: Bridging Observational Studies and Randomized Trials for Health Decision-Making. Submitted to *Public Health* Nov 2025.

Pedersen E, Fischer H, Verschoor D, Oramalu O, Ryser C, Kronig M, Pabst T, Berger M, **SEGELOV E**, Özdemir B. Adolescents and young adults with cancer in Switzerland: a large single-centre analysis of key care pathways and outcomes by sex and age. 2025 Preprint, submitted Sept 2025 to *JNCI*.

Poursoleymani R, Papathanail I, Brigato L, Raitakari O, Viikari J, Kähönen M, Jokinen E, Laitinen T, Tossavainen P, Thomson R, Magnussen C, **SEGELOV E**, Juonala M, Saner C, Mougiakakou S. 2025. Long-Term Risk Prediction of Type 2 Diabetes Using Early-Life and Genetic Data: A Machine Learning Approach in the Young Finns Study. Submitted Nov 2025 to *Diabetes Care*

Verschoor D, Häfele L, Oramalu O, Berzigotti A, Aebbersold D, Bastiaansen J, Berger M, Catucci D, Huber A, Ineichen B, Kohler A, **SEGELOV E**. 2025. The development of MASLD among survivors of breast or colorectal cancer (EVALUATE): Protocol for a single-center observational cross-sectional study. Submitted Nov 2025 to *BMC Cancer*.

Verschoor D, Pedersen E, Oberson A, Bivins K, Rey E, **SEGELOV E**. 2025. Academic career outcomes and gender differences among academic staff at the Faculty of Medicine, University of Bern. Submitted Nov 2025 *Academic Medicine*.

2025

1. Chia J* and **SEGELOV E***, Deng YH, Wei W, Ho G, Shama A, Ding K, Cheng G, Jeffreys M, Nott L, Zielinski R, Ahn J, Yau T, Chao T, Nabilah S, Ghandi M, Rothwell P, Simes J, Ali R, Toh H. 2025. Aspirin after completion of Standard Adjuvant Therapy for Colorectal Cancer (ASCOLT) – An International Multi-Centre Phase 3 Randomised Double-blind Placebo-controlled Trial. *The Lancet Gastroenterology & Hepatology*.10:3:198-209. *equal contribution, [10.1016/S2468-1253\(24\)00387-X](https://doi.org/10.1016/S2468-1253(24)00387-X)
2. Body A, Lal L, Srihari S, MacIntyre R, Buttery J, Ahern E, Opat S, Leahy M, Hamad N, Milch V, Turville S, Smith C, Lineburg K, Rawlinson W, **SEGELOV E**. 2025. Immune Response to COVID-19 Vaccination in Children with Cancer. *Pediatrics*.156 (3), e2024070209
3. Body A, Lal L, Srihari S, MacIntyre R, Buttery J, Ahern E, Opat S, Leahy M, Hamad N, Milch V, Turville S, Smith C, Lineburg K, Rawlinson W, **SEGELOV E**. 2025. Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. *Vaccine* 46 (2025): 126547.
4. Xi X, Lui L, Tuano N, Tailhades J, Mouradov D, Sieber O, Cryle M, **SEGELOV E**, Rosenbluh J. 2025. SRP19 and the protein secretion machinery is a targetable vulnerability in cancers with APC loss 2025. *Proceedings of the National Academy of Sciences* 122.15 (2025): e2409677122
5. Verschoor D, Pedersen S, Tardit A, **SEGELOV E**. 2025. An overview of clinical trials in anal cancer 1999 – 2024. *ESMO Gastrointestinal Oncology*, 100145.
6. Pedersen S, Verschoor D, Tardit A, **SEGELOV E**. 2025. Incidence and burden of anal cancer – time to fight the growing disparities. *ESMO Gastrointestinal Oncology*, 100147.

7. Seghers S, Mandó P, Eid M, Tan CJ, Jayraj A, Jatwani K, Faisal M, Luong V, Young J, Teuwen LA & **SEGELOV E**. 2025. Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022. *JCO Oncology Practice* OP-24.
8. Burge M, Espinoza D, Sjoquist K, Sui D, Mercieca-Bebber R, Chantrill L, Karapetis C, Steer C, Yip S, Cuff J, Winata S, Tie J, Thaker D, Srivastav R, Adbi E, Strickland A, **SEGELOV E**, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt N. 2025. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab plus 5-Fluorouracil as first-line therapy for older patients with RAS and BRAF wild type metastatic colorectal cancer. A study by the Australasian Gastro-Intestinal Trials Group (AGITG). *Clinical Colorectal Cancer* 24 (2), 120-128
<https://doi.org/10.1016/j.clcc.2024.11.003>
9. Michael, M, Wong R, Gill S, Strickland A, Pavlakis N, Shapiro J, Link E, Farrell M, Ngan S, Tie J, Goldstein D, Ngan S, Heriot A, Link E, Farrell M, Neeson PJ, Ramsay RG, Wilson K, Mitchell C, Pavlakis N, Zalcberg J, **SEGELOV E**. 2025 The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab plus Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer. *Clin Cancer Res* (2025) 31 (16): 3452–3462.
10. Manfrida S, Dinapoli L, De Luca V, Chiloiro G, Romano A, Chieffo DPR, **SEGELOV E**, Franco P, Gambacorta MA. 2025. Patients' perspective in anal cancer. *ESMO Gastrointestinal Oncology*, p.100203.
11. Bivins K, Guyon A, **SEGELOV E**. An Approach to Implementing Patient and Public Involvement in Investigator Initiated Clinical Trials". 2025. *Swiss Medical Weekly* 155 (6), 4563-4563
<https://doi.org/10.57187/s.4563>
12. Jin F, Poynten I, Hillman R, Law C, Molano M,... **SEGELOV E**... 2025. Does use of anal cytology as a triage test improve the performance of high-risk human papillomavirus screening in gay and bisexual men for anal cancer prevention? *International Journal of Cancer*, 156(3):575-586.

2024

13. Tan S, Spear E, Sane N, Chan J, Nelson A, Alamgeer A, Nerlekar N, **SEGELOV E**, Nicholls S. 2024. Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study. *Heart, Lung and Circulation*. 33:5: 721-9
14. Teuwen L, Ahmad Z, **SEGELOV E**. Time to Update- Requesting inclusive submission categories for Oncology Research. *JCO Global Oncology*. 10, e2400136.
15. Alessy S, Özdemir B, Martina D, Folorunso S, Bourlon M, Prenan H, **SEGELOV E**. 2024. Intersectionality between country, gender and funding in authorship for phase 3 trials presented at the American Society of Clinical Oncology Annual Meeting 2022. *JCO Global Oncology*. 10: Oct 2024.
16. McPhee, N; Leach, M; Harris, S; Nightingale, C; **SEGELOV E**; Ristevski, E. 2023. Differences in cancer clinical trial activity and trial characteristics at metropolitan and rural trial sites in Victoria, Australia. *Australian Journal of Rural Health*. Published online 17 Mar 2024.
17. Anaka A, Chan D, Pattison S, Thawer A, Franco B, Moody L, Jackson C, **SEGELOV E**, Singh S. 2024. Patient priorities concerning treatment decisions for advanced neuroendocrine tumours identified by discrete choice experiments. *The Oncologist*. 29:3, 227–234.

18. Blennerhassett R, Hamad N, Grech L, Kwok A, Choi T, Forsyth C, Jagger J, Opat S, Harris S, Chan B, Nguyen M, Bain N, Day D, **SEGELOV E**. 2023. Attitudes towards COVID-19 vaccination in adults with haematological malignancies. *Acta Hematologica*, published online February 16, 2024.
19. Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L, Van Dijkum E, Ramage J, **SEGELOV E**, Armstrong T, Niccoli P, Sauvanet A, Falconi M. 2024. Interim analysis of prospective evaluation of the management of sporadic nonfunctioning asymptomatic pancreatic neuroendocrine neoplasms $\leq$ 2 cm (ASPEN study). *Neuroendocrinology*. 10/5/2024
20. Tan S, Chung G, Chan J, Lockwood S, Muthalaly R, Nelson A, Nerlekar N, **SEGELOV E**, Nicholls S, Davis E. 2024. Cancer Screening in Patients with Heart Failure with Reduced Ejection Fraction. *Journal of Asian Pacific Society of Cardiology*. Accepted for publication 10 April 2024.
21. Tan S, Nelson A, Muthalaly R, Ramkumar S, Hamilton J, Nerlekar N, **SEGELOV E**, Nicholls S. 2024. Cardiovascular Risk in Cancer Patients Treated with Immune Checkpoint Inhibitors: Challenges and Future Directions. *European journal of preventive cardiology*. zwae204 13 June 2024.
22. Wang H, Grech L, Wong J, Hoffman D, de Courten B, Sillars B, Savage M, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. 2024. COVID-19 vaccine acceptance, hesitancy, and uptake in people with diabetes in Australia. *Vaccines* 12 (6) 662.
23. Teuwen L, Young J, Alessy S, Özdemir B, Martina D, Folorunso S, Bourlon M, Prenan H, **SEGELOV E**. 2024. Intersectionality between country, gender and funding in authorship for phase 3 trials presented at the American Society of Clinical Oncology Annual Meeting 2022. *JCO Global Oncology*. published online 3 Oct 2024.
24. Samuel R, Rodriguez-Bigas M. et al. International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set. *eClinicalMedicine*, Volume 78, 102939.

2023

25. Tan S, S Sivakumar S, **SEGELOV E**, Nicholls S, Nelson A. 2023. Cardiovascular Risk Factor Reporting in Immune Checkpoint Inhibitor Trials: A systematic review. *Cancer Epidemiology* 83, 102334.
26. Grech L, Kwok A, Nguyen M, Winkel A, Butler E, Allan M, Bain N, **SEGELOV E**. 2023. COVID-19 Vaccine Status, Intent, Hesitancy, and Disease-Related Beliefs in People with Multiple Sclerosis. *Vaccines* 11 (2), 410.
27. Choi T, Chan B, Grech L, Kwok A, Webber K, Wong J, Nguyen M, Bain N, Day D, McCartney A, Hamer R, **SEGELOV E**. 2023. Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model. *Vaccines* 2023, 11, 239.
28. Day D, Toh HC, Ali R, Foo E, Simes J, Chia J, **SEGELOV E**. 2023. Operational challenges of an Asia-Pacific academic oncology clinical trial. *JCO Global Oncology*. 2023-06-26
29. Martin D, **SEGELOV E**. Improving Equity Across Cancer Care Continuum in Asia Pacific. *JCO Global Oncology*. 2023-06-26.
30. Collins I, Blum R, **SEGELOV E**, Parente P, Underhill C. 2022. Workforce challenges across Victorian Medical Oncology Services— Review consultations and workload. Response from the authors. *Internal Medicine Journal*. DOI: 10.1111/imj.16119

31. Tan S, Spear E, Sane N, Nelson A, Nerlaker N, **SEGELOV E**, Nicholls S. 2023. Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors. *J Hum Hypertens* 37 (11), 1043-1046.
32. Tan S, Spear S, Sane N, Chan J, Nelson A, Nerlekar N, **SEGELOV E**, Nicholls S, 2023. Atherosclerotic Cardiovascular Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study. *Heart, Lung, Circulation*. 2023 Dec 1.
33. Zhu H, Hao S, Tseng I, Shen J, del Campo E, Davies A, **SEGELOV E**, Kui Q, Chen Y, Song S, Zhao K. 2023. Interim PET/CT during multimodality treatment of locally advanced esophageal cancer: A scoping review. *Quantitative Imaging in Medicine and Surgery* 2023:13:9.
34. Donoghue M, Body A, Wakefield C, Ahern E, **SEGELOV E**. SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Quality of Life, Toxicity and Vaccine Beliefs Substudy Statistical Analysis Plan. medRxiv, 2023.02. 28.23286595
35. Body A, Martin C, Busijal L, Lal L, Ahern E, MacIntyre C, **SEGELOV E**, SARS-CoV-2 post-vaccine surveillance studies in Australian children and adults with cancer: SerOzNET Statistical Analysis Plan. medRxiv, 2023.02. 26.23286261

2022

36. Arulananda S, **SEGELOV E**. 2022. Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers. *Annals Oncology*, invited editorial 33:669-71.
37. Collins I, Blum R, **SEGELOV E**, Parente P, Underhill C. 2022. Workforce challenges across Victorian Medical Oncology Services. *Internal Medicine Journal*. **2022 Dec 26**
38. Tan S, Day D, Nicholls S, **SEGELOV E**. 2022. Atherosclerotic Cardiovascular Risk with Combination Avelumab and Axitinib. *Journal of Clinical Oncology* 2022 Jun: 40 (29), 3467-3469.
39. Tan S, Day D, Nicholls S, **SEGELOV E**. 2022. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: *JACC: CardioOncology* State-of-the-Art Review. *Cardio Oncology* 4 (5), 579-597.
40. Domen A, Van Paesschen C, Zwaenepoel K, Lambin S, Pauwels P, Rasschaert M, **SEGELOV E**, Peeters M, Prenen H. 2022. Excellent response to MEK inhibition in of a patient with a rare carcinoma harbouring an AGK-BRAF gene fusion. *Anticancer Research*, 2022: 42:1:373-379.
41. Body A, Ahern E, Lal L, Gillett K, Abdullah H, Opat S, O'Brien T, Downie P, Turville S, Munier C, Smith S, MacIntyre C, **SEGELOV E**. 2022. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). *BMC Infectious Diseases* 22.1:1-10.
42. Nguyen M, Bain N, Grech L, Choi T, Harris S, Chau H, Freeman D, Kwok A, McCartney A, Webber K, Day D, **SEGELOV E**. 2022. COVID-19 vaccine hesitancy in patients with solid organ and blood cancers: a multi-centre study. *Asia-Pac J Clin Oncol* Jan 18.
43. Bourlon M, Jimenez B, Castro-Alonso, Bourlon C, Matar C, Gunn E, Ginsburg O, Lopes G, **SEGELOV E**. Global oncology authorship and readership patterns. *JCO Global Oncology* 2022:8; p. e2100299.
44. Menon S, Davies A, Frentzas S, Hawkins C, **SEGELOV E**, Day D, Markman B. 2021. Recruitment,

outcomes and toxicity trends in phase 1 oncology trials: six year experience in a large institution *Cancer reports* 5:2, Feb 2022 e1465

45. **SEGELOV E**, Grunen M, Sebag-Montefiore D, Rao S, Johnsson A, Franco P, Deutsch E, Arnold D, Spindler K. 2022. Global Multidisciplinary team meetings: challenging cases virtual forums from the International Multidisciplinary Anal Cancer Conference (IMACC). *Clinical Colorectal Cancer* Mar 3.
46. Franco P, **SEGELOV E**, Johnsson A, Reichelmann R, Grønlie Guren M, Das, P, Rao S, Arnold D, Spindler KL, Deutsch E, Sebag-Montefiore D. 2022. A machine learning-based bibliometric analysis of the scientific literature on anal cancer. *Cancers* 2022 Mar 27;14(7):1697.
47. Nguyen M, **SEGELOV E**, Goldstein D, Pavlakis N, Shapiro J, Price T, Nagrial A, Chantrill L, Leong T, Burge M, Karapetis C, Chau I, Lordick F, Renouf D, Tebbutt N, Roy A. 2022. Update on optimal management for pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international Faculty. *Expert Review of Anticancer Therapy*. 22:1, 39-51.
48. He J, Jackson C, Hung T, Clarke K, Deva S, **SEGELOV E**, Chao T, Dai M, Yeh H, Ma W, Kramer D, Chan W, Kwan R, Cutler D, Zhi J. 2022. Population Pharmacokinetics for Oral Paclitaxel in Patients with Advanced/Metastatic Solid Tumors. *Pharmacometrics & Systems Pharmacology* Apr 26.
49. McPhee N, Nightingale C, **SEGELOV E**, Harris SJ, Ristevski E. 2022. Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review. *Clinical Trials* 2022 19, 4: 464-476.
50. Foo T, Goldstein D, **SEGELOV E**, Shapiro J, Pavlakis N, Desai J, Yip D, Zalberg J, Price T, Nagrial A, Chantrill L, Burge M, Karapetis C, Tebbutt N, Roy A. 2022. Management of Advanced Gastrointestinal Stromal Tumour (GIST): expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG). *Targeted Oncology* (2022):1-16.
51. Day D, Grech L, Nguyen M, Bain N, Kwok A, Harris S, Chau H, Chan B, Blennerhassett R, Nott L, Hamad Nm Tognela A, Hoffman D, McCartney A, Webber K, Wong J, Underhill C, Stillars B, Winkel A, Savage M, Loe B, Day D, Freeman D, **SEGELOV E**. 2022. Attitudes and beliefs associated with COVID-19 vaccine uptake, intent and hesitancy in people with serious underlying medical conditions. *Vaccines*.10:851.
52. Partelli S, Ramage J, Massironi S, Zerbi A, Kim H, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kalstas G, Bertani E, Sauvanet A, **SEGELOV E**....Falconi M. 2022. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm:interim analysis of prospective ASPEN trial 2022. *British Journal of Surgery*, 109 (12), 1186-1190.
53. Nguyen M, Li M, Travers A, **SEGELOV E**. 2021. Role of chromogranin A in the diagnosis and follow-up of neuroendocrine tumors: real world experience. *Pancreas*. 51 (8), 1007-1010.
54. Grech L, Loe B, Day D, Freeman D, Kwok A, Nguyen M, Bain N, **SEGELOV E**. 2022. The Disease-Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a measure to assess disease-related COVID-19 vaccine attitudes and concerns. *Behavioral Medicine* 15 June 2022: 1-10.
55. Luong V, Ho C, Aedo V, **SEGELOV E**. 2022. Gender Profile of Principal Investigators in a large Academic Clinical Trials Group. *Frontiers in Surgery*, 1042.
56. Pavlakis N, Tincknell G, Lim L, Muro K, Obermannova R, Lorenzen S, Chua Y, Jackson C, Karapetis C,

Price T, Chantrill L, **SEGELOV E**, Lordick F. 2022. European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer- current practice and new directions. *Therapeutic Advances in Medical Oncology* 14 (2022): 1758835922111887.

57. Bain N, Nguyen M, Grech L, Day D, McCartney A, Webber K, Kwok A, Harris S, Chau H, Chan B, Nott L, Hamad N, Tognela A, Underhill C, Loe B, Freeman D, **SEGELOV E**. 2022. COVID-19 vaccine hesitancy in Australian patients with solid organ cancers. *Vaccines*, 2022 Sep;10(9):1373.
58. Body A, Milch V, McSorley L, Lal L, Ahern E, Ryan R, Smith G, Keefe D, **SEGELOV E**. 2022. Rapid Protocol Development, Study Startup and Enrolment of a Prospective Study of COVID-19 Vaccination for Patients with Cancer: A Collaborative Approach. *Vaccines*, 2022, 10, 2003.

2021

59. Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden AK, Nguyen K, Lim S, McCormack L, Lyons SD, **SEGELOV E**, Abbott JA. Fractionated Laser for Vaginal Atrophy Symptoms: A Randomized, Double-Blind Placebo Controlled Study. *JAMA*. 2021;326(14):1378-1380
60. **SEGELOV E**, Carrington C, Aranda S, Currow D, Zalcbler J, Heriot A, Mileschkin L, Bashford J, Coutsouvelis J, O’Kane C, Sulkowski A, Wale J, Hancock S., Bichel-Findlay J, Millar J, Emery J, Zhang P, Collopy B, Cooper S. 2021. Developing clinical indicators for Oncology: the inaugural indicator set for The Australian Council on Healthcare Standards *Med J Aust* 214 (11) 21 June 2021
61. Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant M, Pook D, Ng N, Graham LJ, Mangiola S, **SEGELOV E**, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T, Sathianathan S, Hauser C, Horvath L, Azad A. 2021. Prognostic utility of a whole blood androgen-receptor based gene signature in metastatic castrate-resistant prostate cancer. *European Urology Focus*. 7:1:63-70.
62. Hanna C, Robles-Zurita J, Briggs A, Harkin A, Kelly C, Allan K, McQueen J, Pearson S, Hollander N, Glimelius B, Salazar R, **SEGELOV E**, Saunders M, Iveson T, Jones J, Boyd K. 2021. Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost effectiveness and budget impact analysis. *Clinical Colorectal Cancer*. 20:3: 236-244
63. Davies A, Lum C, Ragu R, Ansell E, Webber K, **SEGELOV E**. 2021. Anti-cancer therapy made easier: a 25-year update. *Int Med J*. 51 473–480.
64. Body A, Tipping-Smith S, Lam M, Prenen H, **SEGELOV E**. 2021. The role of neoadjuvant therapy in locally advanced colon cancer. *Cancer Management and Research*. 13: 2567-2579.
65. Muhandiramge J, Vu T, Wallace M, **SEGELOV E**. 2021. The experiences, attitudes and understanding of research amongst medical students at an Australian medical school. *BMC Medical Education*. 21 (1):1-10.
66. Dettailleur S, Del Re M, Prenen H, **SEGELOV E**. 2021. Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single center study. *Annals of Gastroenterology*. 2021;34(1):68.
67. Jackson C, Hung T, **SEGELOV E**, Barlow P, Prenen H, McLaren B, Hung N, Clarke K, Chao T, Dai M, Yeh H, Cutler, D, Kramer D, He J, Zhi J, Chan W, Kwan R, Deva S. 2021. Oral paclitaxel with encaequidar compared to intravenous paclitaxel in patients with advanced cancer: a randomised crossover pharmacokinetic study. *Br J Clin Pharmacol*. 87, 12: 4670-4680.
68. Kwan E, Fettke H, Crumbaker M, Docanto M, To S, Bukczynska P, Mant M, Ng N, Foroughi S, Graham L-J, Haynes A-M, Azer S, Lim E, **SEGELOV E**, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T,

- Sathianathen S, Hauser C, Horvath L, Joshua A, Azad A. 2021. Whole blood GRHL2 expression as a prognostic biomarker in metastatic prostate cancer. *Translational Andrology and Urology*. 10.4: 1688
69. Meessen S, Currey N, Jahan Z, Parker H, **SEGELOV E**, Dahlstrom J, Kohonen-Corish M. 2021. MSH-3 tetranucleotide repeat instability is inversely associated with the CpG island methylator phenotype *Cancers*. 13(14), 3529
 70. Davies A, Foo M, Gan CL, Kouranbas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, **SEGELOV E**, Bradley J, Soo G, Ramdave S, Kwan E, Azad A. 2021. ⁶⁸Ga-prostate specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. *Asia-Pac J Clin Oncol* 18:5: E204-210.
 71. Kanajapan Y, Blinman P, Underhill C, Karikios D, **SEGELOV E**, Yip D. Medical Oncology Group of Australia Position Statement: COVID-19 vaccination in patients with solid tumours 2021. *IMJ*. 51:955-959.
 72. Davies A, Garvey G, Diaz A, Gurney J, **SEGELOV E**. Cancer care disparities among Australian and New Zealand First Nation Peoples. 2021. *Current Opinion in Supportive & Palliative Care*. 15.3:162-8.
 73. Grønlie Guren M, Sebag-Montefiore D, Franco P, Johnsson A, **SEGELOV E**, Deutsch E, Rao S, Garm Spindler KL, Arnold D. 2021. Treatment of squamous cell carcinoma of the anus, unresolved areas and future perspectives for research. *Clinical Colorectal Cancer*. 20.4: 279-287.
 74. Body A, Ahern E, **SEGELOV E**. 2021 COVID-19 vaccinations for patients with cancer- many remain unvaccinated despite having priority in the vaccine rollout. *Internal Medicine Journal* 51.10: 1760-1760
 75. Sui H, Tebbutt N, Chanthrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, **SEGELOV E**, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. 2021. MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). *BMC Cancer*. 21(1):1-9.
 76. Masoumi-Moghaddam S, Lundy J, Gao H, Rathi V, Swan M, Desmond C, Bhutani MS, Southey MC, Vaughan R, Varma P, Tagkalidis P, Holt BA, C Pilgrim CH, **SEGELOV E**, Lee B, Harris M, Strickland A, Frentzas S, Zalcborg J, Jenkins B, Croagh D. 2021. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. *Endosc Ultrasound*. 10(5):335
 77. Elston M, Love A, Kevat D, Carroll R, Siow Z, Pattison S, **SEGELOV E**, Wyld D, Strickland A, Ransom D. 2021. Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. *Cancer Medicine*. 2021;10:8405–8411.
 78. Body A, Latham S, Kong JB, Raghunath A, **SEGELOV E**. 2021. Stage III colon cancer: is neoadjuvant chemotherapy ready for prime time? A narrative review of neoadjuvant chemotherapy for colon cancer. *Dig Med Res* 8 July 2021.
 79. Body A, Chaunumant H, **SEGELOV E**. 2021. Colorectal cancer- moving forward one step at a time. *Dig Med Res* 8 July 2021.

2020

80. Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladlley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, **SEGELOV**

- E. 2020. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. *Journal of Thoracic Oncology* 15:10 (2020): 1577-1598.
81. Rao S, Sclafani F, Eng C, Grønlie Guren M, Adams R, Benson A, Sebag-Montefiore D, **SEGELOV E**, Bryant A, Peckitt C, Roy A. 2020. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT. *J Clinical Oncology* 38(22), 2510-2518
 82. And Reply to S Kim, et al. (letter to Editor) *J Clinical Oncology* 2020
 83. Symonds EL, Pedersen SK, Murray D, Byrne SE, Roy A, Karapetis C, Hollington P, Rabbitt P, Jones FS, LaPointe L, **SEGELOV E**. 2020. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. *Cancer*. 126 (7) 1460-1469.
 84. **SEGELOV E**, Underhill C, Prenan H, Karapetis C, Jackson C, Nott L, Clay T, Pavlakis N, Sabesan S, Heywood E, Steer C, Lethborg C, Gan H, Yip D, Karanth N, Karikios D MacIntyre R. 2020. Practical considerations for treating cancer patients in the COVID-19 pandemic. *JCO Oncology Practice* 10.
 85. Bennett S, Soreide K, Golami S, Pessaux P, Teh C, **SEGELOV E**, Kennecke H, Prenen H, Myrehaug S, Callegaro D, Hallet J. 2020. Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic. *Current Oncology*, 27(5):501-511.
 86. **SEGELOV E**, Day D, Prenan H Lopez G, Chia J, Chong HC. Impact of the COVID-19 epidemic on a pan-Asian academic oncology clinical trial. *JCO Global Oncology* 2020: 6.
 87. **SEGELOV E** and Garvey G. Cancer and Indigenous Populations: time to end the disparity. 2020. *JCO Global Oncology*. 6, 80-82.
 88. Lum C, Prenen H, Body A, Lam M, **SEGELOV E**. A 2020 Update of anal cancer: The increasing problem in women and expanding treatment landscape. *Expert Review of Gastroenterology & Hepatology*. 14(8):665-680.
 89. Lim L, Thomas D, Chan D, Wyld D, Cehic G, Macdonald W, Tincknell G, Bailey D, Kuchel A, Du T, Pavlakis N, Davis A, **SEGELOV E**. 2020. Australian experience of peptide receptor radionuclide therapy for lung neuroendocrine tumours. *Oncotarget*, 11(27):2636.
 90. Lam M, Lum C, Smith S, Latham S, Prenen H, **SEGELOV E**. 2020. Refractory metastatic colorectal cancer: current challenges and future prospects. *Cancer Management and Research*. 12 (2020):5819–5830.
 91. Underhill C, Parente P, McArthur G, Heydon A, McLachlan S, Wong Z, **SEGELOV E**. 2020. Towards new models of cancer care in Australia: lessons from Victoria's response in the COVID-19 pandemic. *Int Med J* 50:10:1286-1289
 92. Gordon L, Elliott T, Leyden J, Pavlakis N, Michael M, Mumford J, **SEGELOV E**, Wakelin K, Wyld D. 2020. The economic impact on Australian patients with neuroendocrine tumours. *The Patient - Patient-Centered Outcomes Research*. 13(3):363-373.
 93. Price T, Tang M, Gibbs P, Haller D, Peeters M, Arnold D, **SEGELOV E**, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2020. Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty *Expert Review of Anticancer Therapy* 20(4): 305-324.

94. Bourlon M, Woodruff T, Anazado A, **SEGELOV E**. 2020. Oncofertility as a universal right and a Global Oncology Priority (Editorial). *JCO Global Oncology* 6:314-16.
95. Wang Y; Logan S; Stern K; Wakefield C; Cohn R; Agresta F; Jayasinghe Y; Deans R; **SEGELOV E**; McLachlan R; Gerstl B; Sullivan E; Ledger W; Anazodo A. Supportive Oncofertility Care, Psychological Health and Reproductive Concerns: A Qualitative Study. 2020. *Supportive Care in Cancer*. Feb 1;28(2):809-17.
96. Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M, Marx G, Price T, Reece W, **SEGELOV E**, Tebbutt N. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab [ASCENT]. *PLOS One* 15.3 (2020): e0229900.
97. Lau D, Burge M, Roy A, Chau I, Haller D, Shapiro J, Peeters M, Pavlakis N, Karapetis C, Tebbutt N, **SEGELOV E**, Price T, 2020. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019, *Expert Review of Anticancer Therapy* 20:4, 251-270.
98. Rasschaert M, Vulsteke C, De Keersmaecker S, Dias S, Vandenborne K, Verschaeve V, Vuylsteke P, Van Brussel I, Ravelingien J, Van Dam P, **SEGELOV E**, Peeters M. AMTRA: a home-based monitoring and tailored toxicity management system in Cancer patients: a multicentered experience. 2020. *Supportive Care in Cancer* 29(2), 859-867.
99. Nguyen M, Tipping-Smith S, Lam M, Liow E, Davies A, Prenen H, **SEGELOV E**. 2020 An update on the use of immunotherapy in patients with colorectal cancer. *Expert Review of Gastroenterology & Hepatology* Nov 9: 1-4.
100. Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Paul J, **SEGELOV E**, Haydon A, Iveson T, Stockler M. 2020. Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? *JNCI Cancer Spectrum* Nov 28.
101. Partelli S, Ramage J, Massironi S, Zerbi A, Kim H, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kalstas G, Bertani E, Sauvanet A, **SEGELOV E**....Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤ 2 cm: Study Protocol for a Prospective Observational Study. 2020. *Frontiers in Medicine*, 7:1009.
102. Yu IS, Pereira AA, Lee M, Korphaisarn K, Marshall J, **SEGELOV E**, O'Callaghan C, Lim HJ, Kopetz S, Loree JM. 2020. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. *The Oncologist*. 25 (3), 229-234.

2018-2019

103. Athauda A, **SEGELOV E**, Khan Z, Chau I. Integrative molecular analysis of colorectal cancer and gastric cancer: what have we learnt? *Cancer Treatment Reviews*. 1 Feb 2019, 73, p. 31-40.
104. So Y, Frentzas S, **SEGELOV E**. Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC? *Hepatobiliary Surgery and Nutrition* 2019 Aug 5.
105. Day D, Frentzas S, Naidu C, **SEGELOV E**, Green M Current Utility and Future Applications of ctDNA in Colorectal Cancer. *Advances in the Molecular Understanding of Colorectal cancer*. 6 Feb 2019. **SEGELOV E**. (ed.). In- Tech, 24 p.

106. Woodhouse B, Pattison S, **SEGELOV E**, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Wakelin K, Michael M, Asif T, Price T, Lawrence B. Consensus-derived quality performance indicators for neuroendocrine tumour care. *J. Clin. Med.* 2019, 8, 1455.
107. Yee J, Davis G, Hackett D, Beith J, Wilcken N, Currow D, Emery J, Phillips J, Martin A, Hui R, Harrison M, **SEGELOV E**, Kilbreath S. Physical activity for symptom management in women with metastatic breast cancer: a randomised feasibility trial. *Journal of Pain and Symptom Management.* 58(6), 929-939.
108. Freebody J, Comin G, **SEGELOV E**, Tarlinton L. Multifocal hepatic steatosis mimicking malignancy in two siblings. *JGH Open* 2019, 3:4:346-348.
109. Singh S, Moody L, Chan D, Metz D, Strosberg J, Asmis T, Bailey D, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan S, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, **SEGELOV E**. 2018. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours. *JAMA Oncology* 4.11:1597-1604.
110. Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, **SEGELOV E**. 2018. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. *JAMA Oncology.* 4:583-585.
111. Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, **SEGELOV E**, Glimelius B. SCOT: a comparison of cost-effectiveness from a largerandomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. *British Journal of cancer.* 2018 Nov;119(11):1332-8.
112. MacIntyre CR., Costantino V, Chen X, **SEGELOV E**, Chughtai, A, Kelleher A, Kunasekaran, M, Lane JM. Influence of population immunosuppression and past vaccination on smallpox reemergence.2018. *Emerging infectious diseases.* 24:4:646-653.
113. Chan DL, Moody L, **SEGELOV E**, Metz D, Strosberg J, Pavlakis N, Singh S. 2018. Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and the North American Neuroendocrine Tumor Society (NANETS). *Neuroendocrinology.*107 (2018): 32-41.
114. Shapiro J, Thavaneswaran S, Underhill C, Robledo K, Karapetis C, Day F, Nott L, Jefford J, Chantrill L, Pavlakis N, Tebbutt N, Price T, Khasraw M, Van Hazel G, Waring P, Tejpar S, Simes J, Gebiski V, Desai J, **SEGELOV E** 2018. Cetuximab alone or with irinotecan for refractory KRAS-, NRAS, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study. *Clinical Colorectal Cancer.* 17(4), 313-319.
115. Chi, W, Warner R, Chan D, Singh S, **SEGELOV E**, Strosberg J, Wisnivesky J, Kim M. 2018. Long- term outcomes of Gastroenteropancreatic Neuroendocrine Tumors. *Pancreas.* 47:321-25.
116. Au L, Grant M, Haydon A, **SEGELOV E**, Antill Y, Oliva, Wilkins S, P McMurrick P, J Shapiro J. 2018. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: a cohort study of two cancer centres. *International Journal of Surgery.* 51:71-5.
117. Price T, Tang M, Gibbs P, Haller D, Peeters M, Arnold D, **SEGELOV E**, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2018. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. *Expert Review in Anticancer Therapy* 18(4):339-49.

118. Price T, Tang M, Gibbs P, Haller D, Peeters M, Arnold D, **SEGELOV E**, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2018. Targeted therapy for metastatic colorectal cancer. *Expert Review in Anticancer Therapy*. 18:10: 991-1006.
119. Chin-Lenn L, **SEGELOV E**, De Boer RH, Marx GM, Hughes TM, McCarthy NJ, White S, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Mann B. 2018. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable. *Asia-Pacific J Clin Oncology* 14:6: 410-416.
120. Gibbs P, V Heinemann, NK Sharma, J Taieb, J Ricke ... **SEGELOV E**, ...Casado A. 2018 .Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. *Clinical colorectal cancer*. 17 (4): e617-e629.
2014-2017
121. **SEGELOV E**, Lordick F, Goldstein D, Chantrill L, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price T. 2017. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: Expert perspectives from the Australian Gastrointestinal Trials Group with invited international faculty. *Expert Review in Anticancer Therapy*. 17:951-64.
122. Chan DLH, **SEGELOV E**, Wong RSH, Smith A, Herbertson RA, Li B, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. *Cochrane Database of Systematic Reviews* 2017 Issue 6, Art: CD007047.
123. Chan D, **SEGELOV E**, Ferone D, Albertelli M, Pavlakis N, Singh S. 2017. Escalated dose somatostatin analogues for anti-proliferative effect in GEP-NETS: A systematic review. *Endocrine*. 57:366-75.
124. Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, **SEGELOV E**. 2017. Uncommon anal neoplasms *Surgical Oncology Clinics of North America* 26:143-61.
125. Chan D, **SEGELOV E**, Singh S. 2017. Everolimus in the management of metastatic neuroendocrine tumors. *Therapeutic Advances in Gastroenterology*. 10:132-41.
126. Sandler C, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, **SEGELOV E**, Boyle FM, Chin MTM, Barry BK, Webber K, Lloyd AR. 2017. Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue. *Journal of Pain and Symptom Management*. 54:74-84.
127. Strosberg J, Halfdanarson T, Bellizzi A, Chan J, Dillon J, Heaney A, Kunz P, O'Dorisio T, Salem R, **SEGELOV E**, Howe J, Pommier R, Brendtro K, Mohammad Bashir M, Singh S, Soulen M, Tang L, Zacks J, Yao J, Bergsland E. The North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. *Pancreas* 46:707-14.
128. Templeton DJ, Roberts JM, Poynten IM, Law C, **SEGELOV E**, Templeton M, Thurloe, JK, Tong WWY, Varma R. Prevalence and predictors of unsatisfactory anal cytology tests in a cohort of gay and bisexual men in Sydney, Australia: Baseline findings from the Study of the Prevention of Anal Cancer (SPANC). 2017. *European Journal of Cancer Prevention*. 26:212-16.
129. Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J... **SEGELOV E**,.. & Wilson, C. (2017). First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a

- combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncology*, 18(9), 1159-1171.
130. **SEGELOV E**, Thavanewaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. 2016. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro- intestinal trials group ICECREAM study. *Journal of Clinical Oncology* 34(19), 2258-2264.
 131. Kerr RS, Love S, **SEGELOV E**, Johnstone E, Hewitt P, Weaver A, Church DN, Scudder C, Pearson S, Julier P, Tomlinson I, Domingo E and Kerr DJ. 2016. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label randomised phase 3 trial. *Lancet Oncology*. 17:1543-57.
 132. **SEGELOV E**, Waring P, Desai J, Wilson K, Gebiski V, Thavanewaran , Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Tejpar S, Tebbutt N, Shapiro J. 2016. Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS wild type or G13D mutation. ICECREAM: The Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation. *BMC cancer* 16.1 (2016): 1-8.
 133. **SEGELOV E**, Chan D, Lawrence B, Pavlakis N, Kennecke H, Jackson C, Law C, Singh S. 2017. Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process with Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. *Journal of Global Oncology*. 3:380-88.
 134. Singh S, Asa S, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, **SEGELOV E**, Rayson D. 2016. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: An Evidence-Based Canadian Consensus. *Cancer Treatment Reviews*. 47:32-45.
 135. Price T, Thavanewaran S, Burge M, **SEGELOV E**, Haller D, Punt C, Arnold D, Karapetis C, Tebbutt N, Pavlakis, N, Gibbs P, Shapiro J. 2016. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. *Expert Review of Anticancer Therapy*. 16:557-71.
 136. Pangon L, Ng I, Giry-Laterriere M, Currey N, Morgan A, Benthani F, Al-Sohaily S, **SEGELOV E**, Parker B, Cowley M, Wright D, St Heaps L, Carey L, Rooman I, Kohonen-Corish M, Tran P. 2016. JNK is a positive regulator of beta-catenin transcriptional activity commonly over-expressed in colon, breast and ovarian cancer. *Oncogene*. 35:2834-41.
 137. Thavanewaran S, Shapiro J, **SEGELOV E**. 2016. Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced oesophago-gastric tumours? *Translational Cancer Research*. 5:S1214-21.
 138. MacHalek D, Poynten M, Jin F, Hillman R, Templeton D. Law, C, Roberts J, Tabrizi, S, Farnsworth, A; Fairley C, **SEGELOV E**, Grulich A, On behalf of the SPANC Study Team. 2016. A composite cytology-histology endpoint allows a more accurate estimate of anal high-grade squamous intraepithelial lesion prevalence. *Cancer Epidemiology Biomarkers and Prevention*. 25:1134-43.
 139. Chan DL, Espinoza D, Chan J, Lee A, Faisal W, **SEGELOV E**, Pavlakis N. Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. The Cochrane Database of Systematic Reviews. 2016 Dec;2016(12)

140. Chan DL, Pavlakis N, Roach P, Bailey D, Arena J, **SEGELOV E**. 2016. Pancreatic neuroendocrine tumours – a rare pancreatic tumour. *Cancer Forum*. 40 (1):34-9.
141. Molano M, Tabrizi, S, Garland S, Roberts J, MacHalek D, Phillips S, Chandler D, Hillman R, Grulich A, Jin F, Poynten M, Templeton D, Cornall A, SPANC Study Team, **SEGELOV E**, Fairley C. 2016 CpG methylation analysis of HPV16 in laser capture microdissected archival tissue and whole tissue sections from high grade anal squamous intraepithelial lesions: A potential disease biomarker. *PloS one* 11, 8,e016073
142. Machalek D, Jin F, Poynten M, Hillman R, Templeton D, Law C, Roberts J, Tabrizi, S, Garland S, Farnsworth A, Fairley C. Grulich A, **SEGELOV E**, SPANC Study Team. 2016 Prevalence and risk factors associated with high-grade anal squamous intraepithelial lesions (HSIL)-AIN2 and HSIL-AIN3 in homosexual men. 2: 97-105.
143. Roberts, J. M., Jin, F., Thurloe, J. K., Ekman, D., Adams, M. K., McDonald, R. L., . **SEGELOV E...** & Study of the Prevention of Anal Cancer (SPANC) Study Team. (2016). The value of a transformation zone component in anal cytology to detect HSIL. *Cancer cytopathology*, 124(8), 596-60.
144. Tong W, Shepherd K, Garland S, Meagher A, Templeton D, Fairley C, Jin F, Poynten M, Zaunders J, Hillman R, Grulich A, Kelleher A, Carr, A, ...**SEGELOV E**...On behalf of the SPANC Study Team. 2016. Human Papillomavirus 16–Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions. *The Journal of Infectious Diseases*. 211 (3) p405-415.
145. Ferraro D, Goldstein D, O’Connell R, Sjoquist K, Tebbutt N, Grimison P, McLachlan S, Lipton L, Vasey P, Gebiski V, Aiken C, Cronk M, Ng S, Karapetis C S, Pike R, Varma S, **SEGELOV E**, Shannon J. & the Australasian Gastro-Intestinal Trials Group. 2016. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer *Cancer chemotherapy and pharmacology*, 78:2:361-367.
146. Chan D, Pavlakis, N Shapiro J, Price T, Karapetis C Tebbutt N, **SEGELOV E**. 2015. Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review of the literature. *PLoS ONE* 10: e0135599.
147. Burmeister, E. A., O’Connell, D. L., Beesley, V. L., Goldstein, D., Gooden, H. M., Janda, M., Neale, R. E. on behalf of Pancreatic Patterns of Care Study Group- **SEGELOV E**. 2015. Describing patterns of care in pancreatic cancer a population-based study. *Pancreas*. 44:1259-65
148. **SEGELOV E**, Chan D, Shapiro J, Price T, Burge M, Haller D, Price, T, Karapetis C Tebbutt N, Pavlakis N. 2014. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. *British Journal of Cancer*. 111:1122-31.
149. Soon SS, Chia WK, Chan MLS., Ho GF, Jian X, Deng YH, Tan CS, Sharma A., **SEGELOV E**, Mehta S, Ali R. 2014. Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. *PloS ONE*. 2014 9: e107866.
150. Price T, **SEGELOV E**, Burge M, Haller D, Tebbutt N, Karapetis C, Pavlakis, N, Shapiro J. 2014. Current opinion on optimal treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. *Expert Review of Anticancer Therapy*. 14:1477-93.
151. Al-Sohaily S, Henderson C, Selinger C, Pangon L, **SEGELOV E**, Kohonen-Corish M, Warusavitarne J. 2014. Loss of Special AT-Rich Sequence-Binding Protein 1 (SATB1) Predicts Poor Survival in Patients with Colorectal Cancer. *Histopathology*. 65:155-63.

152. Gibbs P, GebSKI V, Van Buskirk M, Thurston K, Cade D, Van Hazel G, SIFLOX Study Group (SEGLOV E., plus 102 other collaborative authors). 2014. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIFLOX study. *BMC Cancer* 14:897.
153. Liyanage SS, **SEGLOV E**, Malik A, Garland SM, Tabrizi SN...McIntyre C. 2014. A Case-Control Study of the Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma in Australia. *Journal of Oncology*: 2014, [236482]. DOI: 10.1155/2014/236482.
154. Yee J, Davis GM, Beith JM, Wilcken N, Currow D, Emery J, Phillips J, Martin A, Hui R, Harrison M, **SEGLOV E**, Kilbreath SL. Physical activity and fitness in women with metastatic breast cancer. *Journal of Cancer Survivorship*:1-10, 2014.
155. Connolly K, Mann B, Chua B, **SEGLOV E**. 2014. Breast cancer: Screening, prevention, support and other aspects *Modern Medicine South Africa* 39:4: 31-36.
156. Connolly K, Mann B, Chua B, **SEGLOV E**. 2014. Breast cancer: new developments in diagnosis and treatment *Modern Medicine South Africa* 39:4: 31-36.

Pre 2014

157. Price, T. J., **SEGLOV E**. Burge, M., Haller, D. G., Ackland, S. P., Tebbutt, N. C., ... Shapiro, J.D. 2013. Current opinion on optimal treatment for colorectal cancer. *Expert Review of Anticancer Therapy*, 13(5), 597-611.
158. Gyorki, D, Shaw T, Nicholson J, Baker C, Pitcher M, Skandarajah A, **SEGLOV E**, Mann B. Improving the impact of didactic resident training with online spaced education. 2013 *ANZ J Surg*. Jun; 83(6):477-80.
159. Liyanage S, **SEGLOV E** Garland S, Tabrizi S, Seale H, Crowe P, Dwyer D, Barbour A, Newall A, Malik A, MacIntyre CR , 2013. The Role of Human Papillomaviruses in Esophageal Squamous Cell Carcinoma. *Asia Pacific Journal of Clinical Oncology* 9(1):12-28.
160. Liyanage SS, Rahman B, Ridda I, Newall AT, **SEGLOV E**, Tabrizi SN, Garland SM, Tabrizi SN, Seale H, Crowe PJ, Moa A, MacIntyre CR. 2013 The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. *PloS one* 8:7:e69238.
161. Liyanage SS, Li Q, Zheng Y, Seale H, Crowe PJ, Newall AT, Rahman B, **SEGLOV E**, QU C, Zhao F, Liu J, Gao Z, Shi W, Yang P, Moa A, MacIntyre CR. 2013 The Relationship between Human Papillomavirus and Oesophageal Squamous Cell Carcinoma in China—A Review of the Evidence. *Advances in Infectious Diseases*: 3, 17-34.
162. Connolly K, Mann B, Chua B, **SEGLOV E**. Early breast cancer: New developments in diagnosis and treatment. 2013 *Medicine Today* 14(6):18-24.
163. Connolly K, Mann B, Chua B, **SEGLOV E** Locally advanced and metastatic breast cancer: new developments in diagnosis and treatment. 2013 *Medicine Today*. 14(7): 33-42.
164. Connolly K, Mann B, Chua B, **SEGLOV E**. Breast cancer: Screening, prevention, support and other aspects. 2013 *Medicine Today*. 14(8): 29-36.

165. **SEGELOV E.** Colorectal cancer. 2013. *Cancer Forum.* 37(1) 59-60.
166. Price T, Shapiro JD, **SEGELOV E**, Karapetis CS, Pavlakis N, van Cutsem E, Shah MA, Kang YK, Tebbutt N. Management of advanced gastric cancer 2012 *Expert Rev. Gastroenterol. Hepatol.* 6(2)199–209.
167. Lawley C, Wainswright C, **SEGELOV E**, Lynch J, Beith J, McCrohon J. Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. 2012 *Asia Pacific Journal of Clinical Oncology* 8:1; 95-100.
168. Dear R, Barrett A, Evans A, Simes J, Newsom J, Kent D, Crossing S, Holliday C, **SEGELOV E** Hruby G Tattersall M. 2012. Identifying and prioritising gaps in colorectal cancer trials research in Australia. *Medical Journal of Australia* 197 (9): 507-511.
169. Webber, K., Girgis, A., Bennett, B.K., Bonaventura, T., Boyle, F., Koh, E.S., Friedlander, M., Segelov, E. and Goldstein, D., 2012. Current Care and Needs of Adult Cancer Survivors-a Cross-Sectional Survey. *Asia Pacific Journal of Clinical Oncology* 8: 356-357.
170. Garland S, Tabrizi S, **SEGELOV E**, Dwyer D, and Crowe P. 2011. High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma. *Cancer Epidemiology, Biomarkers & Prevention.* 20:2:408
171. **SEGELOV E**, Clinical Oncological Society of Australia 37th Annual Scientific Meeting 2011 *Cancer Forum*, 35(1) 65.
172. Price TJ, Tebbutt NC, Karapetis CS, **SEGELOV E**, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD. Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. *Clinical colorectal cancer.* 2010 Jan 1;9(1):8-14.
173. Crea P, Pendlebury S, **SEGELOV E**, Yeo B. 2010. How to Treat- Breast Cancer Part 1: *Australian Doctor* 19 Nov p27-33.
174. Crea P, Pendlebury S, **SEGELOV E**, Yeo B. 2010. How to Treat- Breast Cancer Part 2: *Australian Doctor*: 40: 80-84
175. L Bloomfield, A Magney, **SEGELOV E**. Reasons to try ‘RIME’. 2007 *Medical Education* 41 (11):1104–1104.
176. Ward R, Liauw W, **SEGELOV E**, Links, M. Clinical practice and skeletal event rates 2005. *British Medical Journal* 330:769-769.
177. Liauw W, **SEGELOV E**, Lih, A, Dunleavy, R., Links, M., Ward, R. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. 2005 *BMC Cancer*, 5 (1):89-94.
178. **SEGELOV E.** 2006 *Australian Prescriber*, 29 (1): 2-3.
179. Nassif, N.T., Lobo, G.P., Wu, X., Henderson, C.J.A., Morrison, C.D, Eng, C., Jalaludin, B., and **SEGELOV E**. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. 2004 *Oncogene.* 23 (2): 617-628.
180. Kahnoski, K., Khoo, S.K., Nassif, N.T., Chen, J.D., Lobo, G.P., **SEGELOV E**, Teh B. 2003. Alterations

- of the Birt-Hogg-Dube gene (BHD) in sporadic colorectal tumours. *Journal of Medical Genetics*. 40:7:511-515.
181. **SEGELOV E** Investigating a woman with a breast lump. 2001 *Modern Medicine of South Africa*. 2:32-40.
 182. **SEGELOV E** Investigation of the female patient with a breast lump. 2000 *Medicine Today*; 97-103.
 183. **SEGELOV E** Cellular Mechanisms of Sensitivity to Cisplatin. *PhD diss.*, University of Sydney, 1998.
 184. **SEGELOV E**, Mann G, Sandomi A, Harnett P. Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. 1998 *Mutation Research-DNA Repair*. 407:243-252.
 185. **SEGELOV E** Harnett P. Molecular Biology: The failure of DNA repair systems can lead to cancer and hasten the ageing process. 1995 *Today's Life Science* (1033-6893), 7, p. 28.
 186. **SEGELOV E** and Harnett P. DNA repair in the human genome. *Today's Life Sciences*. 1995.
 187. **SEGELOV E** Gibson J, Joshua D, Kronenberg H. 1995 Primary amyloidosis co-presenting with cervical and massive intraabdominal lymphadenopathy. *Leukemia and Lymphoma* 19:519-520.
 188. **SEGELOV E**, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N, Friedlander M. 1994. Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience. *Journal of Clinical Oncology* 12:378-384.
 189. **SEGELOV E**, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N, Friedlander M. Prognostic factors for women with ovarian germ cell tumours- reply. 1994 *J Clin Oncol* 12(8):1738.
 190. Coates, A.S. and **SEGELOV E**. Long term response to chemotherapy in patients with visceral metastatic melanoma. 1994 *Annals of Oncology* 5:249-251.
 191. **SEGELOV E**, Stuart-Harris, R., Bell, D., Tattersall, M., Hutton-Potts, J. and Friedlander, M. A phase II study of carboplatin and cisplatin in advanced ovarian cancer. 1994 *Eur J Gynecological Oncology* XV;4:277-282.
 192. **SEGELOV E.**, Raghavan, D., Coates, A., Kronenberg, H. Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. 1993 *ANZ J Medicine* 23 (6), 718-719.
 193. **SEGELOV E.**, Cox, K.M., Raghavan, D., McNeil, E., Lancaster, L. and Rogers, J. The impact of histological review on clinical management of testicular cancer. 1993 *Br J Urology*. 71:736-738.
 194. Lewis, C.R., **SEGELOV E.**, Goldstein, D. and Friedlander, M.L. Chemotherapy made easier. 1993 *Aust NZ J Med* 23:387-392.
 195. **SEGELOV E**, Tattersall MHN, Coates AS. Redressing the balance – The ethics of not entering a patient on a randomized clinical trial 1992 *Ann Oncol* 3:103-5.
 196. Friedlander M, de Souza P, **SEGELOV E** Risk factors, epidemiology, screening and prognostic factors in female genital cancer. 1992 *Curr Opin Oncol* 4:913-922.
 197. **SEGELOV E**, Coates A.S., McCarthy, W.H. Metastatic melanoma presenting at diagnosis as a

testicular mass. 1992 *Aust NZ J Med* 22:701.

BOOK EDITOR

1. Guyon A, **SEGELOV E**, Bivins K, (Co- Editors). Implementing PPI: Engaging Patients and the Public in Research. under contract. CRC Press. Sept 2025.
2. **SEGELOV E**, (Section Editor). Breast Cancer GQC. Oxford University Press, UK. November 2025.
3. **SEGELOV E**, (Editor). JCM Special Issue Book "Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms" MDPI Books Jan 2021
4. **SEGELOV E**, Rajer M (co- editors). Current Cancer Treatment 2020. IntechOpen Published 24.6.2020 DOI: 10.5772/intechopen.83168
5. **SEGELOV E**, (Editor). Molecular Understanding of colorectal cancer. 2019 IntechOpen, 6.2.19 DOI: 10.5772/intechopen.77960.
6. **SEGELOV E** (Editor, Special Issue): Cancer in Indigenous Populations. *JCO Global Oncology*; Jan 2020.

BOOK CHAPTERS

1. Davies A, Pheely A, McSorely L, **SEGELOV E**. 2022. CRC – Lifestyle factors and the third healthcare revolution). *Oxford Textbook of Colorectal Cancer*, edited by David Kerr, Oxford University Press. In Press 2023.
2. Dider V, Editor. *Breast Cancer Global Quality Care*, 2nd edition. Publication date June 2026, Oxford University Press. **SEGELOV E** Chapter Editor.
3. Balasubramanian A, John A, **SEGELOV E**. 2022 Current state of chemotherapy and immunotherapy regimens in gastric cancer. Invited chapter in *Research and Clinical Applications of Targeting Gastric Neoplasms*. p289-316. Academic Press.
4. Day D, Frentzas S, Naidu C, **SEGELOV E**, Green M. Current Utility and Future Applications of ctDNA in Colorectal Cancer, in *Molecular Understanding of Colorectal Cancer*. ed SEGELOV E 2018 Nov 22. IntechOpen
5. McLaren C, Day D, Croagh D, Strickland A, **SEGELOV E**. *Endoscopic Ultrasound in Pancreatic Cancer*, in *Advances in Pancreatic Cancer*, ed. Luis Rodrigo, IntechOpen, DOI: 10.5772/intechopen.75211.
6. Chan, D., **SEGELOV E**, Singh S. 2017. *Therapy for Metastatic Disease: Ileum. Neuroendocrine Tumors in Real Life*. Springer, Cham, p 305-323.
7. **SEGELOV E** *Case studies: effective clinical teaching*: UNSW Compendium of Good Practice in Learning and Teaching Issue 5 June 2007, p93-11
8. **SEGELOV E**. *Career FAQs: Medicine* 2006.

ABSTRACTS (Posters and Oral Presentations)**2025**

1. Simes J, S. Li I, Day D, Mouradov D, Yip S, GebSKI V, Jeery G, Zielinski R, Nott L, Ho G, Chao T, Rahman N, FooE, Chia J, Toh H, Sieber O, **SEGELOV E**. 735P Adjuvant aspirin for colorectal cancers (CRC) in patients with PIK3CA-mutated and COX-2 overexpressed tumours: The ASCOLT translational study. *Annals of Oncology*. 2025 Sep 1;36:S513-4.
2. Pedersen E, Rossier C, Eychmüller S, **SEGELOV E**, Flidner M. Professional Perspective on the Importance of Advance Care Planning: A Single-Oncology Center Study. Nationaler Palliative Care Kongress, Biel, Switzerland, Nov 2025.
3. Pedersen E, Verschoor D, Bivens K, Häfele L, Oberson A, Oramalu O, Salazar M, **SEGELOV E**. Fighting the leaky pipeline in academia; a Swiss study on gender inequalities in academic careers. Gender Equality and Diversity in Higher Education, Aberdeen, Scotland, June 2025.
4. Pedersen E, Verschoor D, Bivens K, Häfele L, **SEGELOV E**. Career path barriers and facilitators among people habilitated at the Faculty of Medicine, University of Bern 2013 – 2024. Swiss Gender Health Symposium, Bern Nov 2025.
5. Pedersen E, Verschoor D, Bivens K, Häfele L, Oberson A, Oramalu O, Salazar M, **SEGELOV E**. Swiss Gender Health Symposium, Bern Nov 2025.

2024

6. Lee W, Kim I, Oh S, Lomma C, Mercadé M, Dean A, Zervoudakis A, Vicuna B, Yen C, Sampat K, Bullock A, **SEGELOV E**, Paulson A, Peguero J, Hassan H, Delaporte F, Martin L, Amellal N, Melisi D. Efficacy and safety of NALIRIFOX in Asian patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (mPDAC): results from the phase 3 NAPOLI 3 trial. 2024: *Annals of Oncology* 35: S136-7.
7. Roy A, Bright T, Singhal N, Burge, M, **SEGELOV E**, Haydon A, Chantrill L, Michael M, Connell C, Moffat D, Woodman R, Symonds E, Price T, Scott-Hoy A, Richards A, Karapetis C. 2024. Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial. 2024. *Journal of Clinical Oncology* 42: 16S: 4086.
8. Tan S, **SEGELOV E**, McArthurG, Nicholls S. 2024. Statins and Progression of Coronary Atherosclerosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors (SOCRATES): Progress and Updates. 2024. *Heart, Lung and Circulation* 33, S307.
9. Herson M, Chung G, Tan S, Chan J, Lockwood S, Muthalaly R, Nelson A, Nerlekar N, **SEGELOV E**, McArthur G, Nicholls S, Davis E. 2024. Perception of Cancer Screening in Patients with Heart Failure With Reduced Ejection Fraction. *Heart, Lung and Circulation* 33, S304.
10. Webber K, Kwok A, Cook O, Ng s, White M, **SEGELOV E**. EV461/#1027 The impact of real-time patient reported outcome measures on emergency department presentations and overall survival in people with gynaecological cancer *International Journal of Gynecologic Cancer* 2024;34:A331-A332.

11. Ho, G, Nguyen-Dumont T, Putoczki T, Lee B, Chang J, Wu J, Barker H, Eggenhuizen P, Steen J, Bedo J, Frentzas S, Vandenberg C, Hertzog P, Grimmond S, Papenfuss T, Scott C, **SEGELOV E**, Faridi P, Ooi J. High affinity T-cell receptors against HLA-presented cancer antigens using single cell RNA sequencing for precision T-cell receptor therapy. *Lorne International Cancer Conference*, Feb 2024, Melbourne.

2023

1. Chia J, **SEGELOV E**, Deng YH, Wei W, Ho G, Shama A, Ding K, Cheng G, Jeffreys M, Nott L, Zielinski R, Ahn J, Yau T, Chao T, Nabilah S, Ghandi M, Rothwell P, Simes J, Ali R, Toh H. Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial. Oral presentation ESMO 2023. *Annals of Oncology* 2023;34:S1269
2. Body A, Donoghue M, Ahern E, Lal L, Downey P, Leahy M, Fuentes Bolanos N, Anazado A, Padhye B, Hamad N, Wakefield C, **SEGELOV E**. Immune Response to SARS-COV2 vaccination in children and adolescents with cancer. Oral presentation 55th Congress of the International Society of Paediatric Oncology (SIOP 2023), Ottawa Canada. *PEDIATRIC BLOOD & CANCER*: 70: S65-66.
3. Body A, Ahern E, Lineburg K, Smith C, Lal L, Opat S, Macintyre C, Leahy M, Hamad N, Downie P, Leahy Fuentes Bolanos N, Anazado A, Padhye B, Srihari S, **SEGELOV E**. Patterns of T cell response to SARS-CoV-2 vaccination in children and adults with cancer Oral presentation, 17th Vaccine Conference, Glasgow, 2023
4. Verschoor D, Khlebnikov P, Meer F, Trelle S, Amini P, Haas Q, **SEGELOV E**. Equity challenges in research: Unveiling disparities within Anal Cancer Trials. Oral presentation, International Multidisciplinary Anal Cancer Consortium, 2nd Annual Scientific Meeting, Rome, Nov 2023.
5. Michael, M, Wong R, Singh S, Goldstein D, Ngan S, Heriot A, Link E, Farrell M, Neeson PJ, Ramsay RG, Wilson K, Mitchell C, Tie J, Pavlakis N, Zalberg J, **SEGELOV E**. The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data. *J Clin Oncology* 2023;3616-3616.
6. Teuwen LA, Young J, Hudson J, Bourslon M, Davies A, Prenan H, **SEGELOV E**. Endpoints reported in phase 3 randomised clinical trials at ASCO 2022. *J Clin Oncology* 2023;1570-1570.
7. S Tan, S Sivakumar S, **SEGELOV E**, Nicholls S, Nelson A. 2023: Reporting of cardiovascular risk factors in landmark immune checkpoint inhibitor trials. *Journal of the American College of Cardiology* 2023;81 (S8):2168-2168.
8. Tan S, Spear E, Sane N, Chan J, Nerlekar N, **SEGELOV E**, Nicholls S. 2023. Immune checkpoint inhibitors and atherosclerotic cardiovascular events: a retrospective cohort study. *European Heart Journal* 44 (Supplement_2), ehad655. 2687.
9. Body A, Donoghue M, Ahern E, Lal L, Downey P, Leahy M, Fuentes Bolanos N, Anazado A, Padhye B, Hamad N, Wakefield C, **SEGELOV E**. Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer. *Annals of Oncology*, 2023;34:S1104.
10. Day D, Starus A, Gebiski V, Simes J, Hayes T, Padinharakam S, Strickland A, Briscoe K, Varma S, Barnet M, Jackson C, Horvath L, Price T, Tebbutt N, Karki B, Diakos C, Chia J, Toh H, Jones F, **SEGELOV E**. Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. *Annals of Oncology*, 2023;34: S426-S427.

11. Michael, M, Wong R, Singh S, Goldstein D, Ngan S, Heriot A, Link E, Farrell M, Neeson PJ, Ramsay RG, Wilson K, Mitchell C, Tie J, Pavlakis N, Zalberg J, **SEGELOV E**. The Ave-Rec Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable high risk rectal cancers. *Annals of Oncology* 2023;34:S450.
 12. Tan S, **SEGELOV E**, McArthur G, Shackleton M, Nicholls S. Statins and Progression of Coronary Atherosclerosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors (SOCRATES): Rationale and Design. *Heart, Lung and Circulation*. 2023;32:3:S345.
 13. Tan S, Spear E, Sane N, Chan J, Nelson A, Nerlakar N, **SEGELOV E**, Nicholls S. Atherosclerotic Cardiovascular events amongst cancer patients treated with Immune Checkpoint Inhibitors. *Heart, Lung and Circulation*. 2023;32:3:S342.
 14. Mandó P, Jatwani K, Salman M, Seghers S, Eid M, Tan C, Jayraj A, Young J, Teuwen LA, Prenan H, **SEGELOV E**. Application of the ESMO-Magnitude of Clinical Benefit Scale MCBS) to Phase III studies presented at the 2022 ASCO Annual Meeting (ASCO22). *Annals of Oncology* 34: S1711.
 15. Seghers S, Eid M, Tan C, Jayraj A, Mandó P, Jatwani K, Salman M, Young J, Teuwen LA, **SEGELOV E***, Prenan H*. ESMO-Magnitude of Clinical Benefit Scale (MCBS) scores for Phase III trials of adjuvant and curative therapies at the 2022 ASCO Annual Meeting (ASCO22). *Annals of Oncology* 34: S1711.
 16. Verschoor D, Khlebnikov P, Meer F, Trelle S, Amini P, Haas Q, **SEGELOV E**. Duration of breast cancer trials: analysis of predicted versus actual completion date. *Accepted for presentation ESMO Asia 2023*.
 17. Webber K, Kwok A, Ng S, Cook O, White M, **SEGELOV E**. The impact of real-time Patient Reported Outcome Measures (PROMs) on Emergency Department presentations in people with gynaecological cancer. *Accepted for presentation COSA 2023*.
 18. Webber K, Kwok A, Ng S, Cook O, White M, **SEGELOV E**. The impact of real-time Patient Reported Outcome Measures (PROMs) on Emergency Department presentations in people with breast cancer. *Accepted for presentation COSA 2023*.
 19. Hankijjakul A, Body A, Lal L, **SEGELOV E**. A review of COVID-19 infections in Australian adult cancer patients of a health service in Southeast Melbourne who received COVID-19 vaccinations. *Accepted for presentation COSA 2023*.
 20. Ho, G, Nguyen-Dumont T, Putoczki T, Lee B, Chang J, Wu J, Barker H, Eggenhuizen P, Steen J, Bedo J, Frentzas S, Vandenberg C, Hertzog P, Grimmond S, Papenfuss T, Scott C, **SEGELOV E**, Faridi P, Ooi J. A novel multi-omics immunopeptidomics platform to identify immunogenic neoantigens for precision T-cell receptor therapy for cancer. Lorne International Cancer Conference, Feb 2023, Melbourne.
 21. Kwok A, Cook O, Webber K, White M, **SEGELOV E**. Maintaining supportive and survivorship care throughout COVID-19: the role of remote patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). Oral presentation, 4th Victorian Cancer Survivorship Conference, Mar 2023.
- 2021-2022**
22. **SEGELOV E**, Body A, Luong V, Lopez V, Lal L, Abdullah H, Turville S, Niang Z, Opat S, McCuaig R, Rao S, Lineburg K, Smith C, MacIntyre C, Ahern E. Comprehensive humoral and cellular immune assessments to SARS-CoV-2 (wild type, delta and omicron) following two- and three-dose vaccination schedule in a large adult cancer population: SerOzNET study. oral presentation; *Cancer Research*, 82(S12), CT259.

23. **SEGELOV E**, Body, A., Turville, S., Smith, C., Lineburg, K., Rao, S., McCuaig, R., Opat, S., Niang, Z., Lal, L. and Luong, V., 2022. Comprehensive measures of COVID-19 vaccine efficacy in adolescent cancer patients: Results from SerOzNET. *Cancer Research*, 82(S12), CT567.
24. **SEGELOV E**, Body A, Luong V, Lopez V, Lal L, Abdullah H, Turville S, Niang Z, Opat S, McCuaig R, Rao S, Lineburg K, Smith C, MacIntyre C, Ahern E. 2022. Humoral and cellular immune response to wild-type, delta and omicron SARS COV-2 variants following three-dose vaccination schedule in a large cohort of adult patients with cancer. *Journal of Clinical Oncology*, 40:S17 pp.LBA-12065.
25. Body A, Ahern E, Lal L, Abdullah H, Opat S, Downie P, Leahy M, Fuentes-Bolanos N, Padhye B, Hamad N, Milch V, **SEGELOV E**. Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response. *Annals of Oncology*, 2022, 33: S1544.
26. Body A, Luong V, Wakefield C, Donoghoe M, Bolanos N, Anazado A, Grech L, Ahern E, **SEGELOV E**. Patient-reported toxicity and quality of life following SARS COV-2 vaccination in adults and children with cancer. *Journal of Clinical Oncology* 40:16S: LBA 12068.
27. Nguyen M, Bain N, Harris S, Chau H, Kwok A, Grech L, McCartney A, Webber K, Day D, **SEGELOV E**. 2022. Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers. *Journal of Clinical Oncology* 40:4S: 648-648.
28. Day D, Starus A, Sieber O, Prasse D, Lamik A, Fredebohm J, Simes J, Day F, Jeffrey M, Zielinski R, Singh M, Cheong G, Bonventura A, Chia J, Ali R, Toh H, Jones F, **SEGELOV E**. Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial. *Annals of Oncology* 2022;33:S282-3.
29. Nguyen M, Bain N, Grech L, Kwok A, Hamad N, Tognela A, Chan B, Nott L, Chan H, Harris S, Underhill C, Day D, McCartney A, Webber K, **SEGELOV E**. Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake. *Annals of Oncology*, 33, S1280.
30. **SEGELOV E**, Body A, Lal L, Abdulla H, Turville S, Naing Z, Opat S, Leahy M, Balendra J, Hamad N, McCuaig R, Rao S, Lineburg K, Smith C, MacIntyre CR, Milch V, Busija L, Ahern E. Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer. *Annals of Oncology*, 33, p.S1279.
31. Anaka M, Chan D, Pattison S, Thawer A, Franco B, Moody L, Jackson C, **SEGELOV E**, Singh S. Understanding Neuroendocrine Tumor Patient Preferences for Medical Management of Midgut NETs Using Discrete Choice Experiments: A DIRECT NETs Study. *PANCREAS*, 51:3: E57-E57
32. Nguyen, M., Li, M., Travers, A, **SEGELOV E**. 2022. Role of Chromogranin A in the Diagnosis and Follow up of Neuroendocrine Neoplasms: Real World Review. *PANCREAS* 51(3) pp. E50-E50
33. Nguyen M, Bain N, Grech L, Kwok A, Hamad N, Tognela A, Chan B, Nott L, Harris S, Chau H, Underhill C, Day D, McCartney A, Webber K, **SEGELOV E**. Cancer specific influences on vaccination attitude and behavior. 2022 *Supportive Care in Cancer*. 30; S24-25, 2022.
34. Grech L, Loe B, Day D, Freeman D, Kwok A, Nguyen M, Bain N, **SEGELOV E**. The Disease Influenced Vaccine Acceptance Scale-Six: Validation of a measure to assess disease-related COVID-19 vaccine attitudes and concerns. *Supportive Care in Cancer*. 30;S22-23, 2022.
35. Blennerhassett R, Grech L, Hamad N, Kwok A, Nguyen M, Bain N, Day D, Harris S, Chau H, Chan B,

- Nott L, McCartney A, Webber K, Underhill C, Loe B, Freeman D, **SEGELOV E**. Examining COVID-19 vaccination status and vaccine hesitancy in people with blood cancers. *Supportive Care in Cancer*. 30:S19, 2022
36. Grech L, Winkel A, Butler E, Allan M, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. COVID-19 vaccine uptake, intent, hesitancy and disease related beliefs in people with Multiple Sclerosis. In *16TH VACCINE CONGRESS P* (Vol. 2).
 37. Grech L, Wang H, Wong J, Hoffman D, de Courten B, Stillars B, Savage M, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. COVID-19 vaccine hesitancy and status in people with diabetes. In *16TH VACCINE CONGRESS P*, vol. 2.
 38. Ong J, Opat S, Body A, Ahern E, **SEGELOV E**. Immune response to COVID-19 vaccination in patients with haematological malignancies: preliminary results from SerOZNET. Oral presentation, Blood, Annual Scientific Conference of the Haematology Society of Australia and New Zealand, 2022.
 39. Blennerhassett R, Grech L, Hamad N, Kwok A, Nguyen M, Bain N, Day D, Harris S, Chau N, Chan B, Nott A, McCartney A, Webber K, Underhill C, Exploring COVID-19 vaccination status and vaccine concerns in people with haematological malignancies. Poster presentation, Blood, Annual Scientific Conference of the Haematology Society of Australia and New Zealand, 2022.
 40. Wang H, Grech L, Wong J, Hoffman D, de Courten B, Stillars B, Savage M, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. COVID-19 vaccine acceptance, hesitancy, and uptake in patients with diabetes in Australia. Australasian Diabetes Congress 2022.
 41. Grech L, Winkel A, Butler E, Allan M, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. Exploring COVID-19 vaccine uptake, intent, hesitancy and disease-related beliefs in people with Multiple Sclerosis. *Multiple Sclerosis Journal*. 2022, 28 3S:737: EP0875.
 42. Blennerhassett R, Hamad N, Grech L, Forsyth C, Jagger J, Opat S, Harris S, Chan B, Kwok A, Nguyen M, Bain N, Day D, **SEGELOV E**. 2022. Exploring attitudes towards COVID-19 vaccination in adults with haematological malignancies. *Asia-Pacific Journal of Clinical Oncology*. 18: 208-209.
 43. Hudson J, McCartney A, Kwok A, Grech L, Tognela A, Nott L, King R, Nguyen M, Bain N, Chan B, Harris S, Chau H, Hamad N, Underhill C, Williams J, Webber K, Day D, **SEGELOV E**. 2022. COVID-19 vaccine uptake and hesitancy amongst Australian patients with breast cancer. *Asia-Pacific Journal of Clinical Oncology*. 18: 212-213.
 44. Chan B, Choi T, Grech L, Kwok A, Grech L, Kwok A, Webber K, Wong J, Nguyen M, Bain N, Day D, McCartney A, Hamer R, **SEGELOV E**. 2022. Exploring factors influencing COVID-19 vaccine hesitancy among people with cancer: a qualitative analysis. *Asia-Pacific Journal of Clinical Oncology*. 18: 57-58.
 45. Body, A. Lal L, Abdullah H, Turville S, Naing Z, Opat S, Leahy M, Balendar J, Hamad N, McCuaig R, Rao S, Lineburg K, Smith C, MacIntyre CR, Milch V, Busija L, Ahern E, **SEGELOV E**. 2022. Immune response to COVID-19 vaccination in adults and children with cancer: results from the prospective SerOzNET study. *Asia-Pacific Journal of Clinical Oncology*. 18: 91-91.
 46. Body, A. Ahern E, Lal L, Abdullah H, Opat S, Leahy M, Fuentes Bolanos N, Padhye B, Hamad N, Milch V, **SEGELOV E**. Breakthrough COVID-19 infections in patients with cancer from a prospective observational study of COVID-19 vaccine response. *Annals of Oncology*.33:1544.
 47. Day D, Starus A, Lamik A, Sieber O, Begbie S, Bonaventura A, Rai S, Karanth N, Underhill Cm Nott L,

- van Hazel G, van Hagen T, Wong M, Saqib A, Eastgate M, Srivastav R, Chia J, Toh H, Jones F, **SEGELOV E**. Tumour naïve circulating tumour DNA (ctDNA) analysis in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial. *Annals of Oncology*, 33: S710.
48. Teuwen LA, Young J, Hudson J, Bourlon M, Davies A, Prenan H, **SEGELOV E**. Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting. 2022, *Annals of Oncology*, 33: S1609.
 49. Davies A, Buckley D, Raghunath A, Martin K, Prenen H, Cook O, **SEGELOV E**. Adherence optimisation, benefits, and limitations of oral anti-cancer therapy: a systematic review of patient preferences. *Annals of Oncology*, 33:S1541-2.
 50. Luong V, Ho C, Aedo-Lopez V, **SEGELOV E**. Gender trend over time of principal investigators within large Australian cancer clinical trials groups. *Annals of Oncology*, 33:S1541-2.
 51. McPhee N, Leach M, Nightingale C, Harris S, **SEGELOV E**, Ristevski E. Differences in cancer clinical trial characteristics between metropolitan and rural trial sites in Victoria, Australia. *Asia-Pacific Journal of Clinical Oncology*. 18:189
 52. Davies A, Buckley D, Raghunath a, Mrtin K, Prenen H, Cook O, **SEGELOV E**. Adherence optimaisation, benefits and limitations of oral anti-cancer therapy: A systematic review of patient preferences. *Annals of Oncology* 33, S1541-S1542
 53. Lineburg K, Neller M, Ambalathingal G, Le Texier L, Raju J, Swaminathan S, Lekieffre L, Reehan S, Crooks P, Pannikar A, Mohan S, Khadledi P, Srihari S, Body, A, Ahern E, **SEGELOV E**, Khanna R, Smith C. A rapid whole-blood assay to detect SARS-CoV-2-specific memory T-cell immunity following COVID-19 vaccination. Oral presentation, Australian Society of Immunology Annual Scientific Meeting 2022.
 54. Day D, Starus A, Lamik A, Sieber O, Begbie S, Bonaventura A, Rai S, Karanth N, Underhill Cm Nott L, van Hazel G, van Hagen T, Wong M, Saqib A, Eastgate M, Srivastav R, Chia J, Toh H, Jones F, **SEGELOV E**. Tumour naïve circulating tumour DNA (ctDNA) analysis in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial. AGITG Annual Scientific Meeting Nov 2022.
 55. Kwok A, Cook O, Webber K, White M, **SEGELOV E**. Maintaining supportive and survivorship care throughout COVID-19: the role of remote patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). Oral presentation, 4th Victorian Cancer Survivorship Conference, Mar 2022.
 56. Webber K, Cook O, White M, Kwok A, **SEGELOV E** 2021. The impact of the COVID-19 pandemic on patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in an Australian outpatient oncology setting. *J Clin Oncol*: 39:28S:195-195
 57. Nguyen M, **SEGELOV E**. Role of chromogranin A in the diagnosis and follow up of neuroendocrine neoplasms: real world review. (2021). North American Neuroendocrine Tumor Society Annual Scientific Meeting, Oct 2021.
 58. Lam M, Delaney J, **SEGELOV E**. Improving Telehealth Accessibility During the COVID-19 Pandemic in an Australian Oncology Outpatient Service. *Asia-Pacific J Clin Oncol* 2021 Aug 1:17: 21-21.
 59. Ho G, Faridi P, Wu J, Barker H, Nguyen-Dumont T, Chang J, Fell A, Eggenhuizen P, Steen P, Manolitsas T, Frentzas S, Bedo J, Vandenberg C, Papenfuss T, Scott C, Ooi J, **SEGELOV E**. 2021. An integrated

- genomic, proteomic and immuno-peptidomic approach to discover novel tumour neoantigens in an immunologically cold ovarian cancer for personalised T-cell receptor therapy. *Int J Gyn Cancer* 31(4) A31
60. Liow E, McLaren C, Smith S, Latham S, Kong J, Lam M, Lum C, Body A, Briggs P, **SEGELOV E.** 2021. Systemic anticancer treatment changes at the start of the COVID-19 pandemic in a large metropolitan health service. *Clin Cancer Res* 2021: 27: 6:19 Mar 15
 61. Luong V, **SEGELOV E.** 2021. Gender representation in Australian academic Collaborative Cancer Clinical Trials Groups. *Asia-Pacific Journal of Clinical Oncology*. 17(9):82-82
 62. Nguyen M, Bain N, Harris S, Chau H, Kwok A, Grech L, McCartney A, Webber K, Day D, **SEGELOV E.** 2021. CANcer patients' perspectives on coronavirus VACCination Survey (CANVACCS): results of vaccine willingness and uptake in Victoria. *Asia-Pacific Journal of Clinical Oncology*. 17(9):68-68
 63. Webber K, White M, Cook O, Kwok A, **SEGELOV E.** 2021. The impact of remotely completed real-time Patient Reported Outcome Measures (PROMs) on Emergency Department presentations. *Asia-Pacific Journal of Clinical Oncology* 17(9):87-87
 64. **SEGELOV E.** 2021. Gender representation amongst Principal Investigators of trials run by a large academic collaborative group. *Asia-Pacific Journal of Clinical Oncology* 17(9):153-154.
 65. **SEGELOV E.** 2021. COVID-19 Vaccine response in cancer patients. *Asia-Pacific Journal of Clinical Oncology* 17(9):107-107 (oral presentation)
 66. McPhee N, Nightingale C, **SEGELOV E.**, Harris SJ, Ristevski E. Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review. *Asia-Pacific Journal of Clinical Oncology* 17(9):151-151.
 67. Body A, Ahern E, Lal L, Luong V, Abdullah A, **SEGELOV E.** 2021. Seven day patient reported toxicity in patients participating in a prospective study of COVID-19 vaccine response in adults with cancer (SerOzNET). *Asia-Pacific Journal of Clinical Oncology* 17(9):117-117.
 68. Body A, Milch V, Ahern E, Lal L, **SEGELOV E.** 2021. Rapid startup of a clinical trial due to clinical urgency of the COVID-19 pandemic: lessons for the future. *Asia-Pacific Journal of Clinical Oncology* 17(9):117-117.
 69. Luong V, Wright T, Gillet K, Chau H, Duncan J, McDevitt T, **SEGELOV E.** 2021 Challenges in the implementation of COSA Teletrial model in the Monash-Gippsland Teletrial project. *Asia-Pacific Journal of Clinical Oncology* 17(9):149-150.
 70. Georgeiou C, Harris S, **SEGELOV E.** 2021 Monash-Bendigo Teletrials Clinic: facilitating regional patient access to early phase clinical trials. *Asia-Pacific Journal of Clinical Oncology* 17(9):145-145.
 71. Luong V, Ahern E, Body A, Gillett K, Lal L, Abdullah H, **SEGELOV E.** 2021. SerOzNET: assessing COVID-19 vaccine correlates in cancer patients. *Asia-Pacific Journal of Clinical Oncology* 17(9):202-203 (oral presentation).
 72. Harris S, Chau H, Chan B, Offer C, Donohue C, Kwok A, Nguyen M, Bain N, Grech L, McCartney A, Webber K, Day D, **SEGELOV E.** 2021 Australian CANcer patients' perspectives on coronavirus VACCination Survey (CANVACCS). *Asia-Pacific Journal of Clinical Oncology* Text Messaging Recruitment Outcomes 17(9):146-146.

73. Kanajapan Y, Blinman P, Underhill C, Karikios D, **SEGELOV E**, Yip D. 2021. COVID-19 vaccination in patients with solid tumours: development of an Australian position statement. Clinical Oncology Society of Australia ASM 2021. *Asia-Pacific Journal of Clinical Oncology* 17(9):67-67
74. McLaren C, Jennens R, Kosminder S, Lange P, Hayes T, Carr N, Harley D, Bringmann I, Grossman C, Ristevski E, **SEGELOV E**. 2021 Voluntary Assisted Dying (VAD) in Victoria - a retrospective case series assessing the application process. *Asia-Pacific Journal of Clinical Oncology* 17(9):189-189
75. McLaren C, Jennens R, Kosminder S, Lange P, Hayes T, Carr N, Harley D, Bringmann I, Grossman C, Ristevski E, **SEGELOV E**. Voluntary Assisted Dying (VAD) in Victoria - a case series of patient characteristics 2019-2021. *Asia-Pacific Journal of Clinical Oncology* 17(9):189-189.
76. McLaren C, Jennens R, Kosminder S, Lange P, Hayes T, Carr N, Harley D, Bringmann I, Grossman C, Ristevski E, **SEGELOV E**. Voluntary Assisted Dying (VAD) in Victoria - a retrospective case series comparing reasons for application with Canada and Oregon. *Asia-Pacific Journal of Clinical Oncology* 17(9):190-190.
77. Lum C, Tipping-Smith S, Martin K, **SEGELOV E**. 2021 Treatment outcomes in an institutional cohort of female patients with anal squamous cell carcinoma (SCC) undergoing definitive chemoradiation. First International Multidisciplinary anal cancer conference, Denmark, Nov 2021.
78. Michael M, **SEGELOV E**, Chan D, Wyld D, Price T, Ransom D, Tothill R, Link E, Kong G, Hicks R. The potential role of circulating DNA in the management of neuroendocrine tumors: NET Sanguis study ENETs Annual Scientific Meeting March 2021 (virtual)
79. Muhandiramge J, Vu T, Wallace M, **SEGELOV E**. 2020. Building the next generation of clinician-scientists: the experiences, attitudes and understanding of research amongst Australian medical students. Asia Pacific Medical Education Conference (APMEC) 2021.
80. Ho GY, Wu J, Barker H, Nguyen-Dumont T, Chang J, Eggenhuizen P, Stein J, Manolitsas T, Frentzas S, Bedo J, Vandenberg C, Papenfuss T, Scott C, **SEGELOV E**, Ooi J. Whole genome and exome sequencing of a rare ovarian carcinosarcoma identify tumour neoantigens that are targetable with CD8⁺ T cytotoxic cells. Lorne Cancer Conference, Victoria, Feb 2021
81. Ho G, Faridi P, Wu J, Barker H, Nguyen-Dumont T, Chang J, Fell A, Eggenhuizen P, Steen P, Manolitsas T, Frentzas S, Bedo J, Vandenberg C, Papenfuss T, Scott C, Ooi J, **SEGELOV E**, "Ovarian carcinosarcoma engrafted in NSG MHC^{null} mice as a pre-clinical patient derived xenograft (PDX) model to explore personalised T-cell receptor therapy. Melbourne Immunotherapy Network (MIN) 2021 Winter Symposium
82. Webber K, Cook O, Kwok A, White M, **SEGELOV E**. The impact of COVID-19 on the collection of PROMs in an outpatient oncology clinic: from the waiting room to telehealth. COSA PROMS down Under conference 2021, virtual.
83. **SEGELOV E**, Carrington C, Aranda, S.K., Currow, D., Zalcborg, J., Heriot, A.G., Mileschkin, L., Bashford, J., Coutsouvelis, J., O'Kane, C. and Sulkowski, A. Developing clinical indicators for Oncology: The inaugural indicator set for The Australian Council on Healthcare Standards (ACHS). International Forum on Quality and Safety in Healthcare Australasia, virtual symposium, Sept 2021 (held over from 2020)
84. Chan B, Choi T, Grech L, Nguyen M, Bain N, Harris S, Chau H, Freeman D, Kwok A, Williams J, McCartney A, Webber K, Day D, **SEGELOV E**. Exploring factors influencing COVID-19 vaccine hesitancy among patients with cancer: a multi-centre study and qualitative analysis. Psycho-oncology Co-operative Research Group Scientific Meeting, Dec 2021, Australia, oral presentation.

2019- 2020

85. **SEGELOV E**, Carrington C, Aranda, S.K., Currow, D., Zalcborg, J., Heriot, A.G., Mileschkin, L., Bashford, J., Coutsouvelis, J., O’Kane, C. and Sulkowsk, A. Developing clinical indicators for Oncology: The inaugural indicator set for The Australian Council on Healthcare Standards (ACHS). 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p71
86. **SEGELOV E**. Practical considerations for treating cancer patients in the COVID-19 pandemic. 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p81
87. **SEGELOV E**, McLaren C, Liow E, Smith S, Latham S, Kong J, Lam M, Lum C, Body A, Briggs P. 2020. Systemic anticancer treatment changes at the start of the COVID-19 pandemic in a large metropolitan health service. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p91
88. Lum C, Smith S, Martin K, **SEGELOV E**. Treatment outcomes in an institutional cohort of female patients with anal SCC undergoing definitive chemoradiation. 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p153
89. Menon S, Davies A, Frentzas S, Hawkins C, **SEGELOV E**, Day D, Markman B. Recruitment, outcomes and toxicity trends in phase 1 oncology trials: six year experience in a large institution. 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p154
90. **SEGELOV E**, Underhill C, Prenen H, Babin R. 2020. The Oncology Journal Club Podcase- An innovative format delivering oncology education. *Asia-P Journal of Clinical Oncology* 16:S8 p163
91. Davies A, Buckley D, Ragunath A, Martin K, Prenen H, Cook O, **SEGELOV E**. Patient preferences regarding oral anti-cancer therapy: A systematic review. 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p146
92. McLaren, C., **SEGELOV E**, and Ristevski, E., 2020. Voluntary Assisted Dying (VAD) in Victoria: An audit of timings within the application process. *Asia-Pacific Journal of Clinical Oncology*, 16(S8), pp.94-94.
93. McPhee N, **SEGELOV E**, Nightingale C, Harris S Ristevski E. 2020. Access to and availability of cancer clinical trials in Victoria, 2018 *Asia-Pacific Journal of Clinical Oncology* 16: S8 p173
94. Cook O, Webber K, White M, Kwok A, **SEGELOV E**. 2020. Exploring the profile of baseline patient-reported outcome measures and patient-reported experience measures in an outpatient oncology setting. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p200
95. Webber K, Cook O, White M, Kwok A, **SEGELOV E**. Real time collection and use of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in outpatient oncology: barriers, enablers, and impact on consultation length. 2020. *Asia-Pacific Journal of Clinical Oncology* 16: S8 p145.
96. Li FG, Deans R, Nesbitt-Hawes E, Budden AK, McCormack L, Maheux-Lacroix S, **SEGELOV E**, Lyons SD, Abbott JA. Fractionated Laser for Vaginal Atrophy Symptoms: A Randomized, Double-Blind Placebo Controlled Study. *Journal of Minimally Invasive Gynecology*. 2020 Nov 1;27(7): S69.
97. Cook O, Daiyan Y, Yeganeh L, Davies A, Kwok A, Webber K, **SEGELOV E**. Exploration of the use and impact of patient-reported experience measures (PREMs) in oncology settings: A systematic review.

Journal of Clinical Oncology 38 (29_suppl), 166-166

98. McLaren C, **SEGELOV E**, Ristevski E. 2020. 1875P Voluntary assisted dying in Victoria, Australia: A case series. *Annals of Oncology*. 2020 Sep 1;31:S1068
99. Espinar JB, Torri V, Whisenant J, Hirsch FR, Rogado J, de Castro Carpeño J, Halmos B, Ceresoli GL, Rueda AG, Tiseo M, Felip E. LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERA-VOLT (Thoracic cancer international coVID 19 coLLaboraTion). *Annals of Oncology*. 2020 Sep 1;31:S1204-5.
100. Anaka, M., Chan, D., Pattison, S., Thawer, A., Franco, B., Moody, L., Jackson, C., **SEGELOV E**, Singh, S., Understanding the Treatment Preferences of Neuroendocrine Tumor Patients Using Discrete Choice Experiments. (2020): *Pancreas* 49:3 pp. 462-462.
101. Bourlon M, Jimenez B, Matar C, Gunn E, Ginsburg O, Lopes G, **SEGELOV E**. Global oncology authorship and access patterns. (2020): *J Clin Oncol* 38 (15) S:7061-7061.
102. Day D, Chia J, Foo M, Ali R, Toh H, **SEGELOV E**. Operational challenges of engaging the Asian Pacific (APAC) region in an academic oncology clinical trial. *Annals of Oncology* 2020 Nov 1;31:S1280.
103. Gordon L, Elliott T, Leyden J, Pavlakis N, Michael M, Mumford J, **SEGELOV E**, Wakelin K, Wyld D. 2020. The Economic Impact to Patients with Neuroendocrine Tumours. 2020. *Neuroendocrinology* 110 (1) 94-94.
104. Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L, Van Dijkum E, Ramage J, **SEGELOV E**, Armstrong T, Niccoli P, Sauvanet A, Falconi M. Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study) 2020. *Neuroendocrinology* 110, 96-96.
105. Jackson CG, Deva S, Bayston KF, Eden K, McLaren BR, Barlow P, Hung NA, Clarke K, **SEGELOV E**, Chao TY, Dai MS, Yen HT, Ang E, Cutler D, Kramer D, Zhi J, Chan WK, Kwan R, Hung CT.
106. An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours, *Annals of Oncology*: 30, S5, v180-181.
107. Lim L, Thomas D, Chan D, Wyld D, Cehic G, Macdonald W, Tincknell G, Bailey D, Kuchel A, Du T, Pavlakis N, Davis A, **SEGELOV E**. 1401P An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours, *Annals of Oncology*, 30, S5, October 2019
108. Symonds E, Pedersen S, Murray D, Byrne S, Hollington P, Rabbitt P, Jones F, **SEGELOV E**, Lazarus T, Lapointe L, Young G. Performance comparison of the methylated *BCAT1/IKZF1* ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer. 2019 *Journal of Clinical Oncology* 37(15): 3589-3589.
109. Michael, M, Wong R, Singh S, Goldstein D, Ngan S, Heriot A, Link E, Farrell M, Neeson PJ, Ramsay RG, Wilson K, Mitchell C, Tie J, Pavlakis N, Zalcberg J, **SEGELOV E**. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial. 2019 *Journal of Clinical Oncology* 37(15): TPS3622-TPS3622
110. Kwan E, To S, Fettke H, Docanto M, Bukczynska P, Mant M, Waltham M, Pook D, Ng N, Graham L- J, **SEGELOV E**, Mahon K, Davis I, Parente P, Pezaro C, Horvath L, Azad A. Whole blood FOLH1 mRNA

expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC) 2019 *Journal of Clinical Oncology* 2019 37(15):188-188

111. Davies A, Kwan E, Briggs P, **SEGELOV E**. Implementation of an immune-related adverse events (irAE) education program for healthcare professionals at an Australian multisite tertiary health service. 2019 *Asia-Pacific Journal of Clinical Oncology*. 15, S9, p. 191-192
112. Millar J, Zheng H, Collopy B, **SEGELOV E**. The Development of an Australian National Standard Set of Clinical Indicators for Cancer Care to Monitor and Improve Care for Cancer Patients. 2019 *Victorian Integrated Cancer Service Conference*.
113. Bucki T, Srivastava R, Wagner I, **SEGELOV E**, Sherwell S. Determining the feasibility and impact upon patients and clinicians on the use of a comprehensive geriatric assessment in a Geriatric Oncology clinic. 2019 *Victorian Integrated Cancer Service Conference*.

2017-18

114. Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, **SEGELOV E**. 2018. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. *Journal of Thoracic Oncology* 13.10 (2018): S575.
115. **SEGELOV E**, Bergsland E, Card C, Hope T, Kunz P, Laidley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Singh S. 2018. Pulmonary Neuroendocrine (Carcinoid) Tumors: The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET), *Annals of Oncology*. 2018 Oct 1;29(suppl_8).
116. Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Paul J, **SEGELOV E**, Haydon A, Iveson T, Stockler M. 2018. Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? *Journal Clinical Oncology* 36 (15_suppl), 3602-3602.
117. **SEGELOV E**, Sieber O Chia JWK, Williams D. 2018. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. *Journal Clinical Oncology* 36 (4_suppl), 695-695.
118. Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M, Marx G, Price T, Reece W, **SEGELOV E**, Tebbutt N. 2018. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab [ASCENT]. *Journal Clinical Oncology* 36 (4_suppl), 719-719.
119. Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., **SEGELOV E**, Bryant, A., Peckitt, C. and Roy, A., 2018. LBA21 InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-An International Rare Cancers Initiative (IRCI) trial. *Annals of Oncology*, 29(suppl_8)424-022.

120. La C, **SEGELOV E**, McLeod V, Grewal G. An expanded role oncology pharmacist adds value to symptom and urgent review clinics. 2018 *Asia-Pacific Journal Clinical Oncology* Vol. 14.
121. Gan C, Gruner J, **SEGELOV E**. Survey on patterns of travel for patients attending chemotherapy day units in Monash Health-A local experience. 2018 *Asia-Pacific Journal Clinical Oncology* 14:113-113.
122. Lie G, **SEGELOV E**, Srivastava R. Implementation of a validated chemotherapy prediction tool in a busy oncology clinic. 2018 *Asia-Pacific Journal Clinical Oncology* 14:118-119.
123. Lum C, Rogers S, Sharma K, Marshall L, Sherwell S, Franco M, Hadley AM, **SEGELOV E**, Day D. Implementation and results of the Victorian cancer patient experience survey (VCPES) at Monash Health. *Asia-Pacific Journal Clinical Oncology* 2018 Nov 1 Vol. 14, pp. 119-119
124. Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Segelov E, Paul J, Haydon A. Patients' Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile? *Asia-Pacific Journal Clinical Oncology* 2018 Aug 1 Vol. 14, pp. 51-51.
125. Super L, Nguyen H, **SEGELOV E**, McLeod V, Degraives S, Fedele P, Vandenberg K, James K. A Pathway to Improving an Adolescent and Young Adult Oncology Service: Voices of Patients and Parents. 3rd Global Adolescent & Young Adult Cancer Congress. Dec 2018, Sydney.
126. **SEGELOV E**, Earle C, Venook A, Saskin R, Mofid L, Singh S. 2017. Survival by sidedness of metastatic colorectal cancer (mCRC) treated with Epidermal Growth Factor Receptor Antibodies (EGFR-Ab) in the refractory setting: a population-based study of 1509 patients. *Annals of Oncology* 28.suppl_5.
127. Singh S, Moody L Chan DL, Metz D, Strosberg J, **SEGELOV E**. 2017. Follow up recommendations for completely resected Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Consensus Guidelines from the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with the North American Neuroendocrine Tumour Society (NANETS). *Annals of Oncology* 28.suppl_5 (2017)
128. Chan DL, **SEGELOV E**, Moody L, Liu N, Fischer H, Austin P, Singh S. 2017. Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study. *Annals of Oncology* 28.S5
129. Shapiro J, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, **SEGELOV E**. 2017. The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with "Quad WT". *J Clin Oncol* 35 (15) 3572.
130. **SEGELOV E**, Chan DL, Moody L, Metz D, Strosberg J, Singh S. 2017. Development of follow up recommendations for completely resected Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS) (oral presentation). *J Clin Oncol* (2017): 424-424.
131. Chan DL, **SEGELOV E** Ferone D, Albertelli M, Singh S. 2017. Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review. *J Clin Oncol* (2017): 422-422

132. Moody L, **SEGELOV E**, Chan D, Carsley S, Strosberg J, Metz D, Singh S. 2017. Optimising followup after complete surgical resection of Gastrointestinal Neuroendocrine Tumour- a Delphi process to produce expert consensus in an area lacking clinical evidence. *Neuroendocrinology* 105: 336-336.
133. **SEGELOV E**, Chan DL, Moody L, Metz D, Strosberg J, Singh S. 2017. Follow-up in resected gastroenteropancreatic neuroendocrine tumours. AGITG Annual Scientific Meeting, Cairns 2017.

2016-2014

134. **SEGELOV E**, Chan B, Sim H, Ravikumar A, Bailey D, Chan D, Lawrence B, McEwan S, Pavlakis N, Singh S, Roach P, Wyld D. 2016. Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS countries. *Annals of Oncology* 27 S 9.
135. **SEGELOV E**, Zielinski R, Asghari R, Simes J, Yip , Coote A, Friend C, Aitken C, Chia JK, Jeffrey M. ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. *Asia-Pacific J of Oncology* 12 p167-8
136. Au L, Grant M, Haydon A, Oliva K, Wilkins S, **SEGELOV E**, Antill Y, Ranchod P, Polglase A, Chin M, Chip F, Skinner S, Roger W, McMurrick P, Shapiro J. Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer. 2016 *Annals of Oncology*, 27 (9).
137. Patel D, Chan DL, Moody L, Metz D, Strosberg J, **SEGELOV E**, Singh S. Optimal Followup Strategy for resected neuroendocrine tumours: a systematic review. 2016. *Annals of Oncology* 27 (9).
138. **SEGELOV E**, Chan D, Harris-Roxas B, Lawrence B, Pavlakis N, Kennecke H, Jackson C, Law C, Singh S. Identifying and prioritising Gaps in Neuroendocrine Tumour Research-results of the Delphi consensus project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS). 2016 *Neuroendocrinology* 103, p120.
139. Singh S, Lawrence B, Chan D, Pavlakis N, **SEGELOV E**, CommNETS: Formation of an International Commonwealth countries NET partnership. *Neuroendocrinology* 2016 Jan 1:103:120.
140. Chan D, **SEGELOV E**, Millican J, Singh S, Pavlakis N. Current trials in Neuroendocrine Tumours: A systematic review. *Neuroendocrinology* 2016 Jan 1: 103: 115.
141. Chin-Lenn L, **SEGELOV E**, De Boer RH, Marx GM, Hughes TM, McCarthy NJ, White S, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Mann B. Indications for, and impact of Oncotype DX on adjuvant treatment recommendations when third party funding is unavailable. *Cancer Res* 2016;76:S4: P5-15-02
142. **SEGELOV E**, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the *KRAS* G13D mutation. ORAL presentation European Cancer Congress, Vienna, Oct 2015 (abstract 32LBA); *Eur J Cancer* 51 (2015): S726.
143. Sandler C, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, **SEGELOV E**, Boyle FM, Chin MTM, Barry BK, Webber K, Lloyd AR: TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue. *Journal Clin Oncology* 33 (15_suppl), 9571.

144. Yee J, Davis GM, Hackett D, Beith J, Wilcken N, Currow D, Emery, J, Phillips J, Martin A, Hui R, Harrison M, **SEGELOV E**, Kilbreath S. 2015. Physical activity for women with metastatic breast cancer: a feasibility study. *Medicine & Science in Sports & Exercise* 47, 5S: 464.
145. Sclafani F, Adams R, Eng C, Benson AB, Glynne-Jones R, Sebag-Montefiore D, Arnold D, Roy A, Guren MG, **SEGELOV E**, ...Rao S. InterAACT: An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus Carboplatin (CBDCA) plus Weekly Paclitaxel (PTX) in Patients with Inoperable Locally Recurrent (ILR) or Metastatic Disease. Annual Scientific Meeting of the American Society of Clinical Oncology, Chicago 2015; *Journal Clin Oncol* 33:3, 2015.
146. Sousa M, Hickey M, Jarvis S, Lombard J, Chirgwin J, **SEGELOV E**, Friedlander M. 2014. PEGASUS: Prevalence and severity of genitourinary symptoms and impact on sexual function and quality of life in postmenopausal women receiving adjuvant endocrine therapy for early stage breast cancer- A prospective study. *Menopause* 21: 1364-1364.
147. Kanjanapan Y, Wills D, Conley R, Gibbs P, Karapetis C, Pavlakis N, Shapiro J, Tebbutt N, **SEGELOV E**. Learning through clinical trials: 2013 and 2014 Preceptorship in Colorectal Cancer (CRC) - an initiative of the Australasian Gastro-Intestinal Trials Group (AGITG) - ORAL presentation, winner of Best of the Best -Education, Clinical Oncological Society of Australia Annual Scientific Meeting, *Asia Pacific J Clin Onc* 10: p.107, 2014.
148. Chan D, Pavlakis N, Shapiro J, Price T, Karapetis C, Tebbutt N, **SEGELOV E**, Efficacy of EGFR Inhibitors in extended RAS wild-type and mutant settings in metastatic colorectal cancer: A meta- analysis. Best of the best posters. Annual Scientific Meeting of the Australian Gastrointestinal Trials Group, Brisbane, Sept 2014.
149. Kanjanapan Y, Wills D, Conley R, **SEGELOV E**. Learning through clinical trials: evaluation of the inaugural Australasian Gastro-Intestinal Trials Group (AGITG) Colorectal Cancer (CRC) Preceptorship. Annual Scientific Meeting of the Australian Gastrointestinal Trials Group, Brisbane Sept 2014.
150. Chan D, Pavlakis N, Shapiro J, Price T, Karapetis C, Tebbutt N, **SEGELOV E**. Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta- analysis. 2014; *Journal Clin Oncol* 32:5s, 2014.18.
151. Chan D, **SEGELOV E**, Shapiro J, Price T, Karapetis C, Tebbutt N, Pavlakis N. 2014. Meta-analysis of outcomes of VEGF and EGFR targeted biological therapy in relapsed metastatic colorectal cancer". *Journal Clin Oncol* 32 (suppl; abstr 534)
152. Shannon J, Goldstein D, Wong N, Chinchin S, Sjoquist K, O'Connell R, Grimison P, McLachlan S, Tebbutt N, Lipton L, Vasey P, Cronk M, Varma S, Jefford M, **SEGELOV E**, Abdi E, Ng S, Karapetis C, Gebbski V, Zalcborg J. 2014. A multi-centre, phase II, open-label, single arm study of panitumumab, cisplatin and gemcitabine in biliary tract cancer: Primary results of the AGITG TACTIC study. *Annals of Oncology*, 25(suppl 4), iv244-iv244.
153. Ip E, Bergamin P, Wong J, Goldstein D, **SEGELOV E**, Aghmesheh K, Haghighi K. Comparable morbidity, mortality and patient long-term survival can be achieved in patients with colorectal liver metastases undergoing 2 stage or downstaging liver resections to patients undergoing routine resections. *The Official Journal of The International Hepato Pancreato Biliary Association*. 2014 Mar 1;16:145.2013-2010

154. Midgley RS, Love S, Potter V, **SEGELOV E**, Church D, Ferry DR, Weaver A, Scudder C, Grumett S, Julier P and Kerr DJ. 2013. Final results from QUASAR2, a multicentre, international randomised Phase III trial of capecitabine (cap) +/- bevacizumab (bev) in the adjuvant setting of Stage II/III colorectal cancer (CRC). Late Breaking Abstract (oral). *Annals of Oncology* 25.suppl 4
155. Chan D, **SEGELOV E**, Shapiro J, Price TJ, Karapetis C, Tebbutt NC, Pavlakis N: Meta-analysis of progression free survival impact of biological therapy in relapsed metastatic colorectal cancer. *Asia Pacific Journal Clin Oncol* 9:S3 p.117, 2013.
156. **SEGELOV E**, Wilson K, Gebiski V, Waring P, Desai J, Nott L, Karapetis C, Hall M, Wasan H, Shapiro J. 2013. The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation. *Asia Pacific J Clin Onc* 9, 155-155
157. Kok, P, Pendlebury S, Smith A, Jarvis S, **SEGELOV E**. A clinical audit of anal cancer in a single tertiary centre over 10 years. Clinical Oncological Society of Australia Annual Scientific Meeting, Nov 2013, Adelaide, *Asia Pacific J Clin Onc*. 9,149-149, 2013.
158. Sandler C, Webber K, Friedlander M, Lewis C, Chin M, Venkateswaran R, **SEGELOV E**, et al. Barriers to recruitment for a post-cancer fatigue intervention study- the TOPS trial. Clinical Oncological Society of Australia Annual Scientific Meeting, Nov 2013, Adelaide, *Asia Pacific J Clin Onc*. 9, 116, 2013.
159. Chan D, **SEGELOV E**, Shapiro J, Price TJ, Karapetis C, Tebbutt NC, Pavlakis N: Meta-analysis of overall survival impact of biological therapy in relapsed metastatic colorectal cancer. Annual Scientific Meeting of the Australian Gastrointestinal Trials Group, Melbourne Sept 2013.
160. **SEGELOV E**, Wilson K, Gebiski V Waring P Tabernero J, Wasan H, Ciardiello F, Desai J, Underhill C, Khasraw M, Nott L, Joubert W, Pavlakis, N, van Hazel G, Chantrill L, Price, T, Jefford M, Haydon A, Shapiro J. ICECREAM: Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation. Annual Scientific Meeting of the American Society of Clinical Oncology, Chicago May 2013; *J Clin Oncol* 31, (suppl); abstr TPS3649), 2013.
161. Webber K, Girgis A, Bennett B, Bonaventura A, Boyle F, Koh E, Friedlander M, **SEGELOV E**, Goldstein D. 2013. The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs). *J Clin Oncol* 31 (15 Suppl): 9602.
162. Yee J, Davis, Beith J, Oh B, **SEGELOV E**, Orme K Wilcken N, Hui R, Harrison M, Currow D, Emery J, Phillips J, Martin A, Segelov E, Kilbreath S Physical activity and fitness in women with metastatic breast cancer American Society of Clinical Oncology Breast Cancer Symposium Sept 2013 San Francisco, Abstract #119544.
163. Sandler C, Horsfield S, McBride R, Bennett B, Hamilton B, Webber K, Mildon S, Tzar C, Friedlander M, Lewis C, Chin M, Venkateswran R, **SEGELOV E**, Bastick P, Boyle F, Lynch J, Thomas D, Liauw W, Goldstein D, Lloyd A. A randomised controlled trial of an optimized multidisciplinary intervention for post-cancer fatigue – TOPS Trial. Flinders Centre for Innovation in Cancer survivorship Feb 2013.
164. Arnold, D HJ Schmoll, J Riera-Knorrenschild, F Mayer... **SEGELOV E**, et al. "Gastrointestinal tumors, colorectal". European Society of Medical Oncology Annual Scientific Meeting, Vienna Sept 2012. *Annals of Oncology* (0923-7534), 23 (suppl 9), p. ix178, 2012
165. Solomon B, Desai J, Scott A, Rosenthal M, McArthur G, **SEGELOV E**, MacDiamid J, Brambhath H.

- 2012 First-in-man, Multicenter, Phase I Trial Evaluating the Safety of First-in-class Therapeutic, EGFR-targeted, Paclitaxel-Packaged Minicells. *Eur J Cancer* 48(6):179
166. Girgis A, Webber K, Bennett B, Bonaventura A, Boyle F, Koh E, Friedlander M, Yee J, Davis, Beith J, Oh B, **SEGELOV E**, Orme K Wilcken N, Hui R, Harrison M, Currow D, Emery J, Phillips J, Martin A, Segelov E, Kilbreath S Goldstein D. Current care and needs of adult cancer survivors. *Asia Pacific J Clin Onc* : 8(S1, 3): 356-357.
 167. Midgley RS, Love S, Potter V, Yee J, Davis, Beith J, Oh B, **SEGELOV E**, Orme K Wilcken N, Hui R, Harrison M, Currow D, Emery J, Phillips J, Martin A, Segelov E, Kilbreath S, Ferry DR, Weaver A, Scudder C, Grumett S, Julier P and Kerr DJ. Capecitabine (CAPE) plus/- Bevacizumab (BEV) in the adjuvant treatment of colorectal cancer (CRC) – first and final toxicity results from the international Phase III Quasar2 trial. European Society of Medical Oncology Annual Scientific Meeting, Vienna Sept 2012 *Annals of Oncology* 23 (S9), 181-182, 2012- ORAL presentation.
 168. Beith J, **SEGELOV E**, Orme K, McLean A, Oh B. 2011. A randomised trial assessing the use of electro-acupuncture for aromatase inhibitor induced arthralgia. *J Clin Oncol*;29:TPS120.
 169. **SEGELOV E**. Use of Molecular Profiling using Oncotype DX(R) in decision making for adjuvant chemotherapy in breast cancer - the largest single practice Australian experience (2010) Annual Scientific Meeting of the Clinical Oncological Society of Australia, Melbourne.
 170. Liyanage S, MacIntyre R, **SEGELOV E**. 2010. Overview of current evidence for the possible aetiological role of human papillomavirus (HPV) in oesophageal squamous cell carcinoma. *Asia Pacific J Clin Onc*: 8(S1, 3): 356-357.
 171. Malik, A. MacIntyre R, **SEGELOV E**, Liyanage S. 2010. Review of the epidemiology of oesophageal adenocarcinomas and squamous cell carcinomas. *Asia Pacific J Clin Onc*: 6, 217.
 172. Balakrishnar B, Glasgow A, Murdoch V, Sandhu S, **SEGELOV E**, Thomas D, Yeo, B. 2010. Uridine triacetate as an antidote for 5-fluorouracil toxicity: an overview *Asia Pacific J Clin Onc* 6, 204.
 173. **SEGELOV E**, Haydon, A, Price T, Jefford M, Walpole E, Yip D, Ransom D, Jeffrey M, Tebbutt N, Wong N. SCOT: Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer. 289. *Asia Pacific J Clin Onc*. 2010: 6, 181.

Prior to 2010

174. Lawley, C., McCrohon, J., Wainwright, C., Lynch, J., Beith, J., **SEGELOV E** Detecting late trastuzumab cardiotoxicity using cardiac magnetic resonance imaging. 2009 *Asia-Pacific Journal of Clinical Oncology*, 5(S2), A196.
175. Liauw W, **SEGELOV E**, Lih A, Links M, Dunleavy R, Ward R. 2005. Outcomes and utilization patterns of intravenous bisphosphonates for bony metastases in patients with advanced breast cancer: results in the off-trial setting. *J Clin Oncol* 23 (S16), 6089.
176. Nassif, N.T., Lobo G.P., Rizos, H and **SEGELOV E**. Involvement of *PTEN* in the tumorigenic pathways of sporadic microsatellite stable colorectal cancers (2003). 15th Lorne Cancer Conference, Lorne, Victoria, Australia.
177. Lobo G.P., Nassif, N.T., Wu, X, J., Eng, C., Henderson, C.J.A., Jalaludin, B., **SEGELOV E**. *PTEN* Mutational Spectra and Expression Profile In Sporadic Microsatellite Stable and Unstable Colorectal

- Cancers. (2003). 15th Lorne Cancer Conference, Lorne, Victoria, Australia.
178. Nassif, N.T., Lobo, G.P., Rizos, H., Azer, M. and **SEGELOV E.** Genetic alterations of *PTEN* in microsatellite stable and unstable sporadic colorectal cancers. (2002) Abstract 190: Cancer Genetics and Tumour Suppressor Genes, Cold Spring Harbour Laboratory. New York, USA.
 179. Lobo, G.P., Wu, X-J., Nassif, N.T., Eng, C., Henderson, C.J.A. and **SEGELOV E.** *PTEN* Gene Expression In Sporadic Colorectal Cancer. (2002). Abstract 162: Cancer Genetics and Tumour Suppressor Genes, Cold Spring Harbour Laboratory. New York, USA.
 180. Nixdorf, S., Nassif, N.T., Lobo, G.P., Azer M. and **SEGELOV E.** Mutations of the *Mxi1* Gene in Sporadic Colorectal Cancer (2002). Abstract: 4th Australian Cancer Gene Analysis and Mutation Detection Workshop, South Australia, Australia.
 181. Lobo, G.P., Nassif, N.T., Henderson, C.J.A., and **SEGELOV E.** Novel Germline and somatic PTEN gene mutations in sporadic colorectal cancer. (2002). Merck Sharp and Dohme (Aust) Research Student Poster Award, UNSW. Australia.
 182. Nassif, N.T., Lobo, G.L. and **SEGELOV E.** Somatic mutation of the PTEN tumour suppressor gene in sporadic colorectal cancer (2001). Abstract 105: Keystone Symposium. The Molecular Medicine of Colorectal Cancer, New Mexico, USA.
 183. Lobo, G.P., Nassif, N.T., Henderson, C.J.A., Wu, X-J. and **SEGELOV E.** Germline and somatic mutation of the PTEN tumour suppressor gene in sporadic colorectal cancer (2001). Abstract 410: 13th Annual Lorne Cancer Conference.
 184. Lobo, G.P., Nassif, N.T., Henderson, C.J.A., Nixdorf, S. and **SEGELOV E.** Role of PTEN in sporadic colorectal cancer: Identification and characterisation of novel germline and somatic mutations (2001). Abstract: Peter MacCallum Cancer Institute Symposium. Molecular and Cell Biology of Cancer.
 185. Lobo, G.P., Nassif, N.T., Henderson, C.J.A., Nixdorf, S. and **SEGELOV E.** PTEN is frequently altered in the germline and soma in sporadic colorectal cancer (2001). Abstract: Peter MacCallum Cancer Institute Symposium. Molecular and Cell Biology of Cancer.
 186. Nassif, N.T., Lobo, G.P. and **SEGELOV E.** Somatic mutation of the PTEN tumour suppressor gene in sporadic colorectal cancer (2001). Keystone Symposium: The Molecular Medicine of Colorectal Cancer, New Mexico, USA.
 187. **SEGELOV E.**, Mann G, Harnett P. Characterisation of a novel cisplatin sensitive mammalian mutant cell line (1995). Keystone Conference on DNA repair, New Mexico, USA, (Abstract published in Journal of Cellular Biochemistry, 21A, Abstr C5-151 p286, 1995).
 188. **SEGELOV E.**, Mann G, Harnett PR. Cisplatin handling in three novel cisplatin-sensitive cell lines (1995). 34th Annual Scientific Meeting of the Australian Society for Medical Research, Sydney.
 189. **SEGELOV E.**, de Fazio A, Mann G, Harnett PR. Cell cycle response of Cisplatin-sensitive Chinese Hamster Ovary mutants (1995). 22nd Annual Scientific Meeting of the Clinical Oncological Society of Australia, Canberra.
 190. **SEGELOV E.**, Mann G, Harnett PR. Characterisation of a novel cisplatin-sensitive mammalian mutant cell line and its handling of cisplatin (1994). 33rd Annual Scientific Meeting of the Australian Society for Medical Research, Melbourne.

191. **SEGELOV E**, Mann G, Harnett P. Drug sensitivities of a novel cisplatin sensitive mammalian cell line (1994). Inaugural Sydney University Faculty of Medicine Research Meeting, Sydney.
192. **SEGELOV E** Cellular and molecular mechanisms of cisplatin resistance (1994). Inaugural Sydney Symposium on Research into Cisplatin, Sydney.
193. **SEGELOV E** Friedlander M. Analysis of patients treated with Cisplatin-based chemotherapy for Ovarian Germ Cell Malignancies (1993). 20th Annual Scientific Meeting of the Clinical Oncological Society of Australia, Perth.
194. **SEGELOV E** Friedlander M. Phase II study of Cisplatin and Carboplatin in advanced ovarian cancer (1993). 20th Annual Scientific Meeting of the Clinical Oncological Society of Australia, Perth.
195. **SEGELOV E**, Raghavan D. Histological Review in Testis Cancer (1992). 19th Annual Scientific Meeting of the Clinical Oncological Society of Australia, Melbourne.

COMPETITIVE RESEARCH GRANTS

2025 Swiss National Science Foundation, Investigator Initiated Trials 2024 call: Randomized placebo-controlled trial to assess efficacies of EMPAgliflozin and personalized dietary counseling for kidney STONE prevention in patients with calcium kidney stones (EMPASTONE). PI's: Fuster D, Bally L, Roth B, Christie A, **Segelov E**. CHF 3'417'589.

2025 ENLIGHT Incubator Grant- TrialLearn – developing a training module for clinical researchers to use and generate real world evidence. Mitchell S, Hemkens, Perriaud J, **Segelov E**. CHF 28'000.

2025 Swiss National Science Foundation, BRIDGE-Proposal PolAInsight: Cancer detection in biopsy tissue. **Segelov E**- Project partner CHF 1'201'642

2025 Swiss National Science Foundation, Investigator Initiated Trials 2024 call: Ticln for the Treatment of coronAry lesioNs - PlAque Regression AnD stabilisation with drug Eluting balloons (TITAN-PARADISE). PI: Marco Valgimigli; **Segelov E**- Project partner CHF 2'068'700.

2025 Advisory Board member (1 of 4) **Segelov E**, Swiss brAInHealth Project, awarded funding from Innosuisse CHF 4'10 000.

2024-7 Evaluation Concurrent Care «CoCa» - Implementierung einer strukturierten gesundheitlichen Vorausplanung im Rahmen der Nachsorge von Krebspatient_innen (Kurzform: CoCa). To undertake project evaluation for Gesundheitsförderung Schweiz zur Prävention in der Gesundheitsversorgung (PGV). CHF 100 000

2023- HORIZON-JU-GH-EDCTP3-2023-01 (EU Horizon EDCTP grant). \$7.88M Euro for the grant consortium; lead institution University of Bern.

2020-23: NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme: **Segelov E** (CIA): Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers- An International, Multi- centre, Double Blind, Randomized Placebo Controlled Phase III Trial \$580 000

2022-2023 Victorian Cancer Agency- PROMS and PREMS in Oncology: **Segelov E** (CIA). \$100 000.

2021-22 Cancer Australia - Approach to Market competitive tender: **Segelov E** (CIA): SerOzNET: SARS-

CoV-2 post-vaccine surveillance studies in Australian adults with cancer \$1,000 000.

2021: AGITG **Segelov E (CIA)**: Innovation grant- ActDNA – translational studies from the international randomized phase III ASCOLT trial in adjuvant therapy of colorectal cancer. \$200 000

2018-21: NHMRC project Grant. Sieber O, **Segelov E (CIB)**: Personalisation of Aspirin Adjuvant Therapy in Patients with Colorectal Cancer \$800,000

2017-20: NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme: **Segelov E (CIA)**: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers- An International, Multi- centre, Double Blind, Randomized Placebo Controlled Phase III Trial \$600 000

2021-23 Heart Foundation Strategic Grant in cardio-oncology. Improving cardiovascular health for Aboriginal and Torres Strait Islander people with cancer: towards optimal, cost-effective and equitable cardio-oncological care in Australia **Segelov E (CIF)** \$999,973.75

2021-23: “SOCRATES” clinical trial of statins in melanoma patients undergoing treatment with an immune checkpoint inhibitor. **Segelov E (CIB)** MRFF. \$1,669,300.28

2019-21 Monash Partners Comprehensive Cancer Collaboration: **Segelov E, Zalcborg J (joint CIA)**: Registry and Real time implementation of Patient reported outcome measures (PROMS) and Patient reported experience measures (PREMS). \$450 000K over 2 years

2019-22: Victorian Dept Health and Human Services: Gippsland Teletrials Project. **Segelov E (CIA)**: \$520 000

2019-22: Victorian Cancer Agency. Croagh D, Southey M, Jenkins B, **Segelov E (CID)**, Rathi V, Holt BA, Pilgriam C, Bhutani M, Tagkalidis P. Using next generation sequencing technology to improve the diagnosis of pancreatic cancer. \$459,446.00

2020 VCA Mid-Career Research Fellowship Application Form Application MCRF20035 CIA Rosenbluh. **Segelov E (AI)**.

2020 Inner Wheel Foundation Australia Trust. Cord Blood Research Grant. Greenall S, Watt A, Ho G, **Segelov E (CID)** \$65 000 over 1 y

2020 Clinical Oncological Society of Australasia: Teletrials grant: \$17000 over 1 year **Segelov E (CIA)**

2019 Tour de Cure Foundation: PROTACs as a novel therapeutic strategy to enable colorectal cancer precision medicine. Rosenbluh, S., Cryle, M. & **Segelov, E** \$200 000K over 1 y

2016-2021 National Medical Research Council, Singapore. CI Chia J; **Segelov E** as named international collaborator (CIB) -\$4.2M for ASCOLT Phase III randomised controlled trial.

2017-2018 Symptom and Urgent Review Clinic (SURC) grant funding round: Department of Health and Human Services, Victorian Government, \$110,000 for 1 year. **Segelov E (CIA)**

2019-21 Cancer Australia Priority-driven Collaborative Cancer Research Scheme: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1. **Segelov E (AI)**

2015 IMPACT Philanthropy Application Program, Perpetual Foundation. **Segelov E (CIA)**, Sieber O. Who benefits from aspirin? A translational study of samples collected on the international ASCOLT adjuvant colorectal cancer aspirin trial. \$102,444 for 1 year.

2014-2018: NHMRC Project grant: Rogers M, Centre J, Phan TG, Jenner AM, **Segelov E (CIE)**: How do bone-active drugs increase patient survival? Garvan Institute. \$593 000

2014-2017: NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme: SCOT: short course oncology treatment. Haydon A, **Segelov E (CIB)**: \$590,253

2013-2016: NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme: **Segelov E (CIA)**: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers- An International, Multi-centre, Double Blind, Randomized Placebo Controlled Phase III Trial \$599 168

2014-2017: NMHRC: Personalised metastatic colorectal cancer medicine: accelerating clinical translation with collaborative meta-analyses based on individual-participant data. A/Prof Christos Karapetis, Associate Professor Michael Sorich, Professor Ross McKinnon, Associate Professor Marc Buyse (CIA); **Segelov E (AI)**, Flinders University \$291,601.

2011: NHMRC/Cancer Australia Priority-driven Collaborative Cancer Research Scheme: Haydon A, **Segelov E**: Short Course Oncology Therapy - A study of adjuvant chemotherapy in colorectal cancer 2011:

Health Workforce Australia grant: Preparation for workforce readiness: \$50000

2009: Health Workforce Australia grant for integration of medical students in the preadmission clinic, St Vincent's Private Hospital \$100 000

2005: UNSW Learning and Teaching Award

2004: UNSW Equity Initiatives Grant: Medical Equity and Diversity Initiative

2002-3: UNSW Goldstar Maintenance award

2000-2: Bowel Cancer Foundation/South West Sydney Colorectal Tumour Group:

2000-3: South Western Sydney Clinical School postgraduate scholarship

INDUSTRY GRANTS

2018-19: Clinical Genomics: funding for postdoctoral fellow over 2 years

2015-20 Principal Investigator for CommNETS: Five year seed funding from Ipsen Pty Ltd -\$1.5 M. 2019

SCOOP: Study of total neoadjuvant Chemotherapy and P32 brachytherapy (**OncoSil**) for **Operable Pancreatic cancer Segelov, E. & Croagh, D.** OncoSil Medical Ltd, \$15,000 for protocol development

2017 AGITG Preceptorship in Upper GI cancer - \$60,000 p.a. awarded for 2017

2013-6 AGITG Preceptorship in Colorectal Cancer - \$260,000

2015-6 ALTG Preceptorship in lung cancer- \$120,000 p.a.

2015- ANZUP Preceptorship in prostate cancer- - \$80,000 p.a.

2015 Principal Investigator for international study: CommNETS: A modified Delphi process to identify Gaps in International Neuroendocrine Tumour Research (\$200,000: Ipsen Pty Ltd)

2011 Principal Investigator for international study ICECREAM: Irinotecan cetuximab response evaluation among patients with G13D mutation. Merck Serono \$1.4 M.

COMPETITIVE GRANTS TO STUDENTS/RESEARCHERS UNDER MY SUPERVISION

2022 Dr Elizabeth Ahern- Royal Australasian College of Physicians (RACP) Research Establishment Fellowship

2022 Dr Gwo-Yaw Ho, RACP Research Establishment Fellowship

2022 Dr Daphne Day, Research Entry Scholarship Royal Australasian College of Physicians

2022 Dr Kate Webber, SMICS 2021 Funding Program

2021 Dr Elizabeth Ahern- Post Graduate scholarship, Faculty of Medicine Nursing Health Sciences, Monash University

2019-21 Dr Gwo-Yaw Ho, School of Clinical Sciences Postgraduate Scholarship

2020 Dr Daphne Day, Research Entry Scholarship Royal Australasian College of Physicians

This demonstrates the calibre of staff that I recruited and mentored.

PHILANTHROPY

Donation for breast cancer investigator led trial 2021- \$350 K

Donation for translational PhD 2021- \$50K

WEEKLY PODCAST

Host of The Oncology Journal Club podcast (available any podcast outlet- #OJC; global audience) > 65 episodes.

Linked In